

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number  
**WO 2005/007877 A2**

- (51) International Patent Classification: **C12Q**
- (21) International Application Number: **PCT/US2004/023789**
- (22) International Filing Date: **19 July 2004 (19.07.2004)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
**60/488,510**      **18 July 2003 (18.07.2003)**      **US**
- (71) Applicant (for all designated States except US): **UNIVERSITY OF MASSACHUSETTS [US/US]; 365 Plantation Street, Worcester, MA 01605 (US).**
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **XU, Zuoshang [US/US]; 11 Ann Drive, North Grafton, MA 01536 (US). XIA, Xugang [US/US]; 293 Turnpike Road, Apt. 118, Westborough, MA 01581 (US).**
- (74) Agents: **MILASINCIC, Debra, J. et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).**
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): **ARIPO (BW, GI, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**  
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **REGULATABLE PROMOTERS FOR SYNTHESIS OF SMALL HAIRPIN RNA**

(57) Abstract: The present invention provides compositions for RNA interference and methods of use thereof. The present invention is based on the development of promoters that can be used to regulate shRNA expression spatially (in specific cells) and temporally (at specific times) in cells or transgenic animals that express a recombinase. The compositions and methods of the present invention feature regulatable promoters that allow for inhibition of the expression of target alleles in a spatially and temporally regulatable manner. Thus, the compositions of the present invention are useful for investigating gene functions, both physiologic and pathologic, in specific cell groups and in specific ages, in normal and disease pathways. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.

**WO 2005/007877 A2**

## REGULATABLE PROMOTERS FOR SYNTHESIS OF SMALL HAIRPIN RNA

### Government Funding

This invention was made with a Government grant from the National Institutes  
5 of Health (R21 Grant No. S111500596A0000). The U.S. Government has certain rights  
in this invention.

### Related Applications

This patent application claims the benefit of U.S. Provisional Patent Application  
10 Serial No. 60/488,510, entitled "Regulatable Promoters for Synthesis of Small Hairpin  
RNA", filed July 18, 2003. The entire contents of the above-referenced provisional  
patent application are incorporated herein by this reference.

### Background of the Invention

15 RNAi can mediate sequence-selective suppression of gene expression in a wide  
variety of eukaryotes by introducing short RNA duplexes (called small interfering RNAs  
or siRNAs) with sequence homologies to the target gene (Caplen *et al.*, 2001; Elbashir *et al.*, 2001c). Recent experiments indicate that small hairpin RNAs (shRNAs) transcribed  
*in vivo* can trigger degradation of corresponding mRNAs similar to the siRNAs (Shi,  
20 2003). These developments raise the possibility that siRNA duplexes or vectors  
expressing shRNAs (small hairpin RNAs) may be used to block the expression of a toxic  
gene.

shRNAs can be synthesized from plasmid constructs directly in cells. A  
common approach uses type III RNA polymerase (Pol III) promoters, one of which is  
25 the U6 promoter, which offers several advantages. First, this class of RNA polymerases  
naturally produces small, non-coding transcripts such as U6 small nuclear RNA  
(snRNA). Second, their natural transcripts are neither capped at the 5' nor  
polyadenylated at their 3' ends, and therefore resemble siRNA. Third, all of their  
promoter elements, which include a distal sequence element (DSE), proximal sequence  
30 element (PSE) and TATA box, are located 5' to the transcription initiation site, thereby  
allowing convenient design of transcript sequences. Fourth, transcription directed by

these promoters initiates at defined nucleotides, *e.g.*, a G for the U6 promoter, and terminates when the transcription encounters four or more Ts in succession. Incidentally, the transcripts also carry 3' overhangs of one to four Us (the termination sequence), a structural feature similar to what has been defined *in vitro* for effective  
5 siRNAs.

The U6 promoter is a strong constitutive promoter. Being able to regulate the U6 promoter (for example, in shRNA expressing constructs) would significantly advance the RNAi field.

Recent work has suggested that Pol II, rather than Pol III, is responsible for  
10 synthesis of micro RNAs (miRNA) *in vivo*. miRNAs are endogenous small RNAs (21-25 nt) that interact with the RISC complex. miRNA are synthesized as large pri-miRNAs, which are processed by endonuclease Drosha in the nucleus to pre-miRNA. The pre-miRNA has a hairpin structure and is exported to the cytoplasm by exportin 5 and Ran GTPase. The pre-miRNA is further processed in the cytoplasm by Dicer to  
15 generate a double stranded miRNA, which unwinds to become single stranded RNA and complexes with the RISC to carry out its functions, such as translational repression and RNAi.

This new understanding in the endogenous miRNA mechanism suggests that Pol II promoters may be useful for synthesis of shRNA because they mimics the endogenous  
20 miRNA production mechanism. Indeed, previous work has shown that the CMV promoter, a viral Pol II promoter, could be used to synthesize small hairpin RNA in mammalian cells (Zeng, 2003). CMV promoter is a strong but constitutive promoter that is not regulated. It is also a viral promoter that works well in cultured cells but poorly *in vivo*, particularly in some adult somatic cells. There is, therefore, a clear need  
25 in the art for the identification of alternative Pol II promoters which may be useful for shRNA synthesis *in vivo*.

### **Summary of the Invention**

The present invention is based on the development of constructs that can be used  
30 to regulate shRNA expression spatially (in specific cells or tissues) and temporally (at specific times) in cells or animals (*e.g.*, transgenic animals). In particular, the invention features constructs that include promoters (*e.g.*, Pol III promoters and Pol II promoters)

that are regulatable by a recombinase (*e.g.*, a recombinase co-expressed in a cell or animal expressing a construct of the invention) or by tetracycline or tetracycline analog. Preferred constructs of the present invention, recombinase or tetracycline (*e.g.*, tetracycline analog) regulatable promoters, provide for inhibition of the expression of mutant target alleles in a spatially and temporally regulatable manner. The constructs of the present invention are useful for investigating gene functions, both physiologic and pathologic, in specific cell groups and/or at specific times. In addition, the technology of the present invention may be used in research and development to investigate both normal and disease pathways.

10       The present invention provides compositions for RNA interference and methods of use thereof. The present invention is based on the development of promoters that can be used to regulate shRNA expression spatially (in specific cells) and temporally (at specific times) in transgenic animals that express a recombinase. The compositions and methods of the present invention feature regulatable promoters that allow for inhibition of the expression of target alleles in a spatially and temporally regulatable manner. Thus, the compositions of the present invention are useful for investigating gene functions, both physiologic and pathologic, in specific cell groups and in specific ages, in normal and disease pathways. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.

20       Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

#### **Brief Description of the Drawings**

Figures 1A-F depict various U6-shRNA transgenic constructs. (A) The basic shRNA expression construct. (B-D) Inducible desilencing constructs: the shRNA is expressed but upon exposure to Cre recombinase the expression will be inhibited. The Neo tail (B) is attached as a PCR marker for detection of transgenes and recombination events. (E, F) Inducible silencing constructs: the shRNA expression is blocked but upon exposure to Cre recombinase the expression will be activated.

30       Figures 2A-B depict the results of testing the U6 promoter modified by *loxP* site insertion. (A) SOD1<sup>G93A</sup>GFP expression was quantified in cell lysates by emission scanning using a fluorometer (n = 3) according to a published protocol (Chiu *et al.*



2002). Cotransfected constructs are indicated in the figure legend. (B) Detection of the transfected SOD1<sup>G93A</sup>-GFP and the endogenous human SOD1 proteins in 293 cells by Western blot.

Figure 3 depicts ubiquitin C promoter-shRNA regulatable constructs.

5        Figure 4 depicts the results of testing the tetracycline regulatable expression vectors UbCP-TRE1-EGFP and UbCP-TRE2-EGFP upon cotransfection with a vector coding for tTS.

Figure 5 depicts the results of testing the mirMSOD2-expressing tetracycline regulatable expression vector UbCP-TRE2-mirMSOD2-tTS-IRES-EGFP following  
10        transfection into cells and addition of doxycyclin.

Figure 6 depicts the structure of the mirMSOD2 shRNA (SEQ ID NO: 1).

Figure 7 depicts the results of testing the tetracycline-regulatable mirMSOD2-expressing vector UbCP-TRE2-mirMSOD2-tTS-IRES-EGFP, and the cre-lox-regulatable mirMSOD2-expressing vector UbCP-lox-RFP-lox-mirMSOD2-EGFP, for  
15        their ability to inhibit endogenous SOD2 gene expression when transfected into cells and the cells are additionally exposed to doxycyclin or cre, respectively.

### **Detailed Description of the Invention**

The present invention features regulatable constructs for the expression of  
20        shRNAs. In particular, the invention features constructs that can mediate RNAi (or gene silencing) in a spatial or temporal fashion. Spatial or temporal regulation is achieved by coexpressing a construct of the invention in a cell or animal which expresses a recombinase. The featured constructs of the invention are capable of being switched from an inactive to active form (or vice versa) upon interaction with the appropriate  
25        recombinase. Exemplary constructs comprise loxP sites which are present in certain orientations such that interaction with the recombinase, Cre, switches the constructs from inactive to active forms (or vice versa). Further featured constructs comprise tetracycline responsive elements. Regulation of shRNA expression is achieved by coexpressing these constructs in a cell or animal which expresses a tetracycline  
30        transcriptional repressor, and upon addition of an inducer (e.g., tetracycline or a tetracycline analog), allows the construct to switch from inactive to active forms.

In one aspect, the invention features inducible desilencing constructs. These constructs have been designed such that they express shRNA against a target gene, but upon exposure to Cre recombinase the shRNA-encoding sequences are excised, thereby stopping the shRNA expression and its silencing of target gene expression. In another aspect, the invention features inducible silencing constructs. These constructs do not express shRNA, but upon exposure to Cre recombinase or to tetracycline (or tetracycline analog), the construct activates and expresses the shRNA, thereby silencing target gene expression. In various embodiments, the shRNA encoding sequence is under the transcriptional control of a Pol III or Pol II promoter.

10 The present invention provides compositions for RNA interference and methods of use thereof. The present invention is based on the development of promoters, e.g., Pol III and Pol II promoters, that can be used to regulate shRNA expression spatially (in specific cells) and temporally (at specific times) in transgenic animals that express a recombinase. The compositions and methods of the present invention feature  
15 regulatable promoters that allow for inhibition of the expression of target alleles in a spatially and temporally regulatable manner. Thus, the compositions of the present invention are useful for investigating gene functions, both physiologic and pathologic, in specific cell groups and in specific ages, in normal and disease pathways. Functional and genomic and proteomic methods are featured. Therapeutic methods are also  
20 featured.

Accordingly, the invention features, in one aspect, a construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the construct further comprising a first loxP site upstream of the promoter and a second loxP site downstream of the shRNA encoding sequence, the loxP sites being in the same  
25 orientation such that the promoter and encoding sequences are excisable upon exposure to Cre.

The invention features, in another aspect, a construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the shRNA encoding sequence comprising a first stem-encoding portion, a loop-encoding portion, and a  
30 second stem-encoding portion, wherein the construct further comprises spacer DNA downstream of the shRNA encoding sequence, a second loxP site downstream of the spacer DNA, and a first loxP site within the loop-encoding portion of the shRNA

encoding sequence, the loxP sites being in the same orientation such that the spacer DNA and second stem-encoding sequence are excisable upon exposure to Cre.

The invention features, in another aspect, a construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the U6 promoter  
5 comprising (a) a distal sequence element (DSE); (b) a proximal sequence element (PSE);  
and (b) a TATA box, operably linked, wherein the construct further comprises a first loxP site downstream of the shRNA encoding sequence, and a second loxP site between the DSE and the PSE, the loxP sites being in the same orientation such that the shRNA encoding sequences and a portion of the promoter comprising the PSE and the TATA  
10 box are excisable upon exposure to Cre.

The invention features, in yet another aspect, a construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the shRNA encoding sequence comprising a first stem-encoding portion, a loop-encoding portion, and a second stem-encoding portion, the loop-encoding portion comprising a first loxP  
15 site operably linked to a transcription termination signal upstream of a spacer DNA and a second loxP site, the loxP sites being in the same orientation such that the first loxP site, termination signal and spacer DNA are excisable upon exposure to Cre.

The invention features, in yet another aspect, a construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the U6 promoter  
20 comprising (a) a distal sequence element (DSE); (b) a proximal sequence element (PSE);  
and (b) a TATA box, operably linked, wherein the construct further comprises a first loxP site and a second loxP site, said sites being interrupted by spacer DNA, between the DSE and the PSE, the loxP sites being in the same orientation such that a loxP site and the spacer DNA are excisable upon exposure to Cre.

25 The invention further features, in one aspect, an inducible desilencing construct for the expression of a shRNA, the construct comprising a promoter element operably linked to a shRNA encoding element and further comprising a first and second recombinase-sensitive element in an appropriate orientation such that all or a portion of the promoter or shRNA encoding element is excisable upon exposure to Cre.

30 In one embodiment of this aspect, the first recombinase-sensitive element is upstream of the promoter and the second recombinase-sensitive element is downstream of the shRNA encoding element.

In another embodiment of this aspect, the first recombinase-sensitive element is within the shRNA encoding element and the second recombinase-sensitive element is downstream of the shRNA encoding element. In one embodiment, the first element is within a loop portion of the shRNA encoding element. In another embodiment, the construct further includes a spacer nucleotide sequence between the shRNA encoding element and the second recombinase-sensitive element. In a preferred embodiment, the spacer is between 50 and 200 nucleotides in length.

In yet another embodiment of this aspect, the first recombinase-sensitive element is within the promoter and the second recombinase-sensitive element is downstream of the shRNA encoding element. In preferred embodiments, the first recombinase-sensitive element is downstream of at least one obligatory element in said promoter or is downstream of a DSE element.

The invention features, in one aspect, an inducible silencing construct for the expression of a shRNA, the construct comprising a promoter element operably linked to a shRNA encoding element, the promoter or shRNA encoding element being interrupted by DNA sequences flanked by a first and second recombinase-sensitive element in an appropriate orientation such that all or a portion of the DNA sequences is excisable upon exposure to Cre.

In one embodiment of this aspect, the DNA sequences flanked by a first and second recombinase-sensitive element are within the promoter. In one embodiment, the promoter is a Pol III promoter. In a preferred embodiment, the promoter is U6 comprising a distal sequence element (DSE), proximal sequence element (PSE) and TATA box. In one embodiment, the DNA sequences flanked by a first and second recombinase-sensitive element are between the DSE and PSE.

In another embodiment of this aspect, the DNA sequences flanked by a first and second recombinase-sensitive element are within the shRNA encoding element. In one embodiment, the DNA sequences flanked by a first and second recombinase-sensitive element comprise a transcription termination signal.

In embodiments of this aspect, the construct further includes a spacer nucleotide sequence between the first recombinase-sensitive element and the second recombinase-sensitive element. Preferably, the spacer is between about 50 and 200 nucleotides in length.

The invention features, in one aspect, an inducible silencing construct for the expression of a shRNA, the construct comprising a ubiquitin C promoter (UbC) operably linked to an intron comprising an shRNA encoding element, the UbC promoter comprising a 5' promoter region and exon 1, operably linked, wherein the construct  
5 further comprises one or more tetracycline responsive elements (TRE) within the 5' promoter region or exon 1.

In one embodiment of this aspect, the construct further comprises a tetracycline transcriptional repressor (tTs) encoding nucleic acid sequence and an internal ribosomal entry site (IRES). In various embodiments, the constructs further comprise a marker  
10 protein encoding nucleic acid sequence.

The invention features, in another aspect, an inducible silencing construct for the expression of a shRNA, the construct comprising a ubiquitin C promoter (UbCP) operably linked to an intron, the UbC promoter comprising a 5' promoter region and exon 1, operably linked, wherein the intron comprises an shRNA encoding element  
15 downstream of a transcription termination signal, and wherein the construct further comprises a first loxP site in said exon 1, and a second loxP site between the transcription termination signal and the shRNA encoding element, the loxP sites being in the same orientation such that a portion of the intron comprising the transcription termination signal is excisable upon exposure to Cre.

In one embodiment of this aspect, the construct further comprises a marker  
20 protein encoding nucleic acid sequence upstream of the transcription termination site. In various embodiments, the constructs further comprise a marker protein nucleic acid sequence downstream of the shRNA encoding element.

The invention features, in yet another aspect, an inducible desilencing construct  
25 for the expression of a shRNA, the construct comprising a ubiquitin C promoter (UbCP) operably linked to an intron, the UbC promoter comprising a 5' promoter region and exon 1, operably linked, wherein the intron comprises an shRNA encoding element upstream of a transcription termination signal, and wherein the construct further comprises a first loxP site in said exon 1, and a second loxP site downstream of the  
30 transcription termination signal, the loxP sites being in the same orientation such that a portion of the intron comprising the shRNA encoding element and the transcription termination signal is excisable upon exposure to Cre.

In one embodiment of this aspect, the construct further comprises a marker protein encoding nucleic acid sequence between the shRNA encoding element and the transcription termination signal. In various embodiments, the constructs further comprise a marker protein encoding nucleic acid sequence downstream of the second  
5 loxP site.

In particular embodiments of these aspects, the marker protein is red or green fluorescent protein.

In one embodiment of these aspects, the recombination-sensitive element is a loxP site.

10 In one embodiment of these aspects, the shRNA comprises a sequence sufficiently complementary to a target mRNA to mediate degradation of said target. In a preferred embodiment, the target mRNA encodes a mutant protein. Preferably, the mutant protein is a disease-causing mutant, e.g., SOD1. In certain embodiments, the mutant protein is SOD1<sup>G93A</sup> or SOD1<sup>G85R</sup>.

15 The invention further features a construct of any one of these aspects for the treatment of a disease. In one embodiment, the disease is caused by aberrant gene function. In a preferred embodiment, the disease is a dominant, gain-of-function mutation. In one embodiment, the disease is a neurological disease.

The invention also features a vector comprising the construct of any one of these  
20 aspects. In one embodiment, the vector is a viral vector, e.g., an AAV or lentivirus.

The invention further features a cell comprising a construct or a vector of any one of these aspects. In a preferred embodiment, the cell is an animal cell.

The invention still further features a nonhuman transgenic animal carrying a transgene comprising the constructs of any one of these aspects. The invention also  
25 provides a nonhuman homologous recombinant animal which contains cells from any one of these aspects.

The invention features, in another aspect, a method for promoting inducible RNAi comprising introducing into a cell a construct of the invention under conditions such that shRNA expression is inducible.

30 In one embodiment, the cell is present in a subject. In another embodiment, the cell is a cultured cell.

In one embodiment, the introducing comprises transfecting said cell. In another embodiment, the introducing comprises infecting said cell with a viral vector.

The invention features, in one aspect, a method of promoting inducible RNAi in a subject, the method comprising administering a construct of the invention.

5       The invention features, in one aspect, a method for selectively inhibiting mutant gene expression *in vivo* or *in vitro*, the method comprising introducing into a host cell a construct of the invention under conditions such that said shRNA is expressed, thereby inhibiting mutant gene expression.

In one embodiment, the shRNA does not inhibit expression of the wild type  
10   allele.

The invention features, in another aspect, a method for treating a disease in a subject, the method comprising administering a construct of the invention, thereby treating a disease in a subject.

In one embodiment, the disease is caused by aberrant gene function. In one  
15   embodiment, the disease is caused by a mutation that is a dominant, gain-of-function mutation.

The invention features, in one aspect, a method for identifying a compound which modulates RNAi, the method comprising contacting a cell comprising a construct of the invention with a test compound, and determining the effect of the test compound  
20   on an indicator of RNAi activity in said cell, thereby identifying a compound which modulates RNAi.

The invention provides, in a related aspect, a compound identified according to the above method.

The invention features, in yet another related aspect, a method for modulating  
25   RNAi, the method comprising contacting a cell expressing a construct of the invention with a compound that modulates RNAi, as identified according to the above method, in a sufficient concentration to modulate the activity of RNAi.

The invention further provides a method for modulating RNAi, the method comprising contacting a cell expressing a construct of the invention with a compound  
30   which binds to said construct in a sufficient concentration to modulate the activity of RNAi.

The invention provides, in another aspect, a method for deriving information about the function of a gene in a cell or organism comprising introducing into said cell or organism a construct of the invention; maintaining the cell or organism under conditions such that RNAi can occur; determining a characteristic or property of said cell or organism; and comparing said characteristic or property to a suitable control, the comparison yielding information about the function of the gene.

The invention features, in one aspect, a method of validating a candidate protein as a suitable target for drug discovery comprising: (a) introducing into a cell or organism z construct of the invention; (b) maintaining the cell or organism under conditions such that RNAi can occur; (c) determining a characteristic or property of said cell or organism; and (d) comparing said characteristic or property to a suitable control, the comparison yielding information about whether the candidate protein is a suitable target for drug discovery.

The invention features, in another aspect, a kit comprising reagents for activating RNAi in a cell or organism, said kit comprising: a construct of the invention and instructions for use.

The invention features, in yet another aspect, a method of excising a DNA sequence, the method comprising exposing a construct of the invention to Cre recombinase and allowing recombination, thereby excising a portion of said DNA sequence.

The invention features, in still another aspect, a method of promoting target gene expression, the method comprising exposing a construct of the invention to a Cre recombinase; excising of a portion of the shRNA flanked by loxP sites; and disrupting expression of the shRNA, thereby allowing the target gene to be expressed.

In one embodiment of this aspect, said disrupted expression results in the silencing of a mutant gene. In a preferred embodiment, the mutant gene is SOD1.

The invention features, in one aspect, a method of recovering promoter function, the method comprising exposing a construct of the invention to a Cre recombinase protein under conditions such that shRNA expression is activated, thereby recovering said promoter function.



The invention features, in another aspect, a method of disrupting promoter function, the method comprising exposing a construct of the invention to a Cre recombinase, and allowing recombination, thereby disrupting promoter function.

The invention features, in yet another aspect, a method of inhibiting expression of a target gene, the method comprising exposing a construct of the invention to a Cre recombinase; activating said promoter; and expressing said shRNA, thereby inhibiting target gene expression.

In one embodiment, the promoter is regulated in an animal. In one embodiment, the promoter is regulated temporally. In another embodiment, the promoter is regulated spatially.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

## **I. Definitions**

So that the invention may be more readily understood, certain terms are first defined.

As used herein, the term "Cre" has its art-recognized meaning, *i.e.*, the enzyme expression product of the cre gene which is a recombinase that effects site-specific recombination of DNA at lox sites. A preferred cre gene is the bacteriophage P1 cre gene as disclosed, for example, in Abremski *et al.*, Cell, 32:1301-1311 (1983), the entire content of which is incorporated herein by reference.

As used herein, the term "lox site" or "loxP site" has its art known meaning, *e.g.*, a nucleotide sequence at which the gene product of the cre gene, referred to herein as "Cre," can catalyze a site-specific recombination. A LoxP site is a 34 base pair

nucleotide sequence which can be isolated from bacteriophage P1 by methods known in the art.

As used herein the term "site-specific recombination" refers to a recombination event that is effected between two specific sites on a single nucleic acid molecule or between two different molecules that requires the presence of an exogenous protein, such as an integrase or recombinase. "Cre-lox site-specific recombination" refers to deletion of a pre-selected DNA segment flanked by lox sites. The term "DNA segment" refers to a linear fragment of single- or double-stranded deoxyribonucleic acid (DNA), which can be derived from any source.

As used herein, the term "encodes" means the generation of a RNA molecule from a DNA molecule (*i.e.*, a complementary RNA molecule generated from the DNA molecule by the process of transcription) or the generation of a polypeptide or protein molecule from a DNA molecule *via* a RNA intermediate (*i.e.*, by the processes of transcription and translation).

The term "construct", as used herein refers to an engineered DNA molecule including one or more nucleotide sequences from different sources. A preferred construct includes at least a shRNA-encoding region operably linked to a promoter sequence.

The term "enhancer" refers to a DNA sequence which, when bound by a specific protein factor, enhances the levels of expression of a gene, but is not sufficient alone to cause expression. An "enhancer" is capable of enhancing expression of a gene regardless of the distance from the gene or orientation relative to the gene.

The term "kit" is any manufacture (*e.g.* a package or container) comprising at least one reagent, *e.g.* a construct, for activating RNAi in a cell or organism, the manufacture being promoted, distributed, or sold as a unit for performing the methods of the present invention.

The term "intron" refers to a sequence that is not translated into protein. An intron is initially transcribed into RNA but is cut out of the message before it is translated into protein.

The term "gene" includes cDNAs, RNA, or other polynucleotides that encode gene products. "Foreign gene" denotes a gene that has been obtained from an organism

or cell type other than the organism or cell type in which it is expressed; it also refers to a gene from the same organism that has been translocated from its normal situs in the genome.

The term “target gene”, as used herein, refers to a gene intended for  
5 downregulation *via* RNA interference (“RNAi”). The term “target protein” refers to a protein intended for downregulation *via* RNAi. The term “target RNA” refers to an RNA molecule intended for degradation by RNAi. An exemplary “target RNA” is a coding RNA molecule (*i.e.*, a mRNA molecule).

The term “promoter” refers to a DNA sequence to which RNA polymerase can  
10 bind and initiate transcription. An “inducible promoter” is a DNA sequence which, when operably linked with a DNA sequence encoding a specific gene product, causes the gene product to be substantially produced in a cell only when an inducer which corresponds to the promoter is present in the cell. The term “Pol III promoter” refers to an RNA polymerase III promoter. Exemplary Pol III promoters include, but are not  
15 limited to, the U6 promoter, the H1 promoter, and the tRNA promoters. The term “Pol II promoter” refers to an RNA polymerase II promoter. Exemplary Pol II promoters include, but are not limited to, the Ubiquitin C promoter and the CMV promoter.

The term “inducible RNAi” refers to RNAi-mediated silencing that can be regulated, *e.g.*, spatially or temporally. Inducible RNAi is intended to encompass both  
20 inducible silencing, *e.g.*, effecting, promoting or stimulating RNAi-mediated silencing, and inducible desilencing, *e.g.*, inhibiting or downmodulating of RNAi-mediated silencing.

The term an “inducible desilencing construct” refers to a DNA sequence which is capable of expressing a shRNA, but upon the occurrence of a site-specific recombinase  
25 mediated event, no longer expresses the shRNA. Upon exposure to a recombinase, *e.g.*, Cre, the DNA sequence, *e.g.*, a portion of the DNA sequence containing the promoter or shRNA encoding element, may be excised, thereby preventing shRNA expression and its silencing of a target gene expression.

The term an “inducible silencing construct” refers to a DNA sequence which is  
30 capable of expressing a shRNA only upon the occurrence of a site-specific recombinase mediated event. Upon exposure to a recombinase, *e.g.*, Cre, the DNA sequence, *e.g.*, the

promoter or shRNA encoding element (*e.g.*, the transgene), is activated such that the shRNA is expressed, thereby silencing expression of a target gene.

The term "expression" of a gene or nucleic acid encompasses not only cellular gene expression, but also the transcription and translation of nucleic acid(s) in cloning systems and in any other context. The term "recombinase" encompasses enzymes that induce, mediate or facilitate recombination, and other nucleic acid modifying enzymes that cause, mediate or facilitate the rearrangement of a nucleic acid sequence, or the excision or insertion of a first nucleic acid sequence from or into a second nucleic acid sequence.

The term "RNA interference" or "RNAi", as used herein, refers generally to a sequence-specific or selective process by which a target molecule (*e.g.*, a target gene, protein or RNA) is downregulated. In specific embodiments, the process of "RNA interference" or "RNAi" features degradation of RNA molecules, *e.g.*, RNA molecules within a cell, said degradation being triggered by an RNA agent. Degradation is catalyzed by an enzymatic, RNA-induced silencing complex (RISC). RNAi occurs in cells naturally to remove foreign RNAs (*e.g.*, viral RNAs). Natural RNAi proceeds *via* fragments cleaved from free dsRNA which direct the degradative mechanism to other similar RNA sequences. Alternatively, RNAi can be initiated by the hand of man, for example, to silence the expression of target genes.

The term "RNA agent", as used herein, refers to an RNA (or analog thereof), comprising a sequence having sufficient complementarity to a target RNA (*i.e.*, the RNA being degraded) to direct RNAi. A sequence having a "sufficiently complementary to a target RNA sequence to direct RNAi" means that the RNA agent has a sequence sufficient to trigger the destruction of the target RNA by the RNAi machinery (*e.g.*, the RISC complex) or process.

The term "RNA" or "RNA molecule" or "ribonucleic acid molecule" refers to a polymer of ribonucleotides. The term "DNA" or "DNA molecule" or deoxyribonucleic acid molecule" refers to a polymer of deoxyribonucleotides. DNA and RNA can be synthesized naturally (*e.g.*, by DNA replication or transcription of DNA, respectively). RNA can be post-transcriptionally modified. DNA and RNA can also be chemically synthesized. DNA and RNA can be single-stranded (*i.e.*, ssRNA and ssDNA,

respectively) or multi-stranded (*e.g.*, double-stranded, *i.e.*, dsRNA and dsDNA, respectively).

The term "mRNA" or "messenger RNA" refers to a single-stranded RNA that specifies the amino acid sequence of one or more polypeptide chains. This information is translated during protein synthesis when ribosomes bind to the mRNA.

The term "target site" of a recombinase is the nucleic acid sequence or region that is recognized (*e.g.*, specifically binds to) and/or acted upon (excised, cut or induced to recombine) by the recombinase. The term "gene product" refers primarily to proteins and polypeptides encoded by other nucleic acids (*e.g.*, non-coding and regulatory RNAs such as tRNA, sRNPs). The term "regulation of expression" refers to events or molecules that increase or decrease the synthesis, degradation, availability or activity of a given gene product.

The term "transcript" refers to a RNA molecule transcribed from a DNA or RNA template by a RNA polymerase template. The term "transcript" includes RNAs that encode polypeptides (*i.e.*, mRNAs) as well as noncoding RNAs ("ncRNAs").

As used herein, the term "small interfering RNA" ("siRNA") (also referred to in the art as "short interfering RNAs") refers to an RNA agent, preferably a double-stranded agent, of about 10-50 nucleotides in length (the term "nucleotides" including nucleotide analogs), preferably between about 15-25 nucleotides in length, more preferably about 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, the strands optionally having overhanging ends comprising, for example, 1, 2 or 3 overhanging nucleotides (or nucleotide analogs), which is capable of directing or mediating RNA interference. Naturally-occurring siRNAs are generated from longer dsRNA molecules (*e.g.*, > 25 nucleotides in length) by a cell's RNAi machinery (*e.g.*, the RISC complex).

The term "shRNA", as used herein, refers to an RNA agent having a stem-loop structure, comprising a first and second region of complementary sequence, the degree of complementarity and orientation of the regions being sufficient such that base pairing occurs between the regions, the first and second regions being joined by a loop region, the loop resulting from a lack of base pairing between nucleotides (or nucleotide analogs) within the loop region.

The term "subject", as used herein, includes living organisms at risk for or having a cell neurological, *e.g.* neurodegenerative disease or disorder. Examples of

subjects include humans, monkeys, cows, sheep, goats, dogs, cats, mice, rats, and transgenic species thereof. Administration of the compositions of the present invention to a subject to be treated can be carried out using known procedures, at dosages and for periods of time effective to modulate RNAi in the subject as further described herein.

5       The term "treatment", as used herein, is defined as the application or administration of a therapeutic agent to a subject, or application or administration of a therapeutic agent to an isolated tissue or cell line from a subject, who has a disease or disorder, a symptom of a disease or disorder, or a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease or disorder, the symptoms of the disease or disorder, or the predisposition toward a disease or disorder. A therapeutic agent includes, but is not limited to, small molecules, peptides, antibodies, ribozymes, antisense oligonucleotides, chemotherapeutic agents and radiation.

15       The term "effective amount", as used here in, is defined as that amount necessary or sufficient to treat or prevent a disorder, *e.g.* a neurological or a neurodegenerative disease or disorder. The effective amount can vary depending on such factors as the size and weight of the subject, the type of illness, or the particular agent being administered. One of ordinary skill in the art would be able to study the aforementioned factors and make the determination regarding the effective amount of the agent without undue experimentation.

20       The term "nucleoside" refers to a molecule having a purine or pyrimidine base covalently linked to a ribose or deoxyribose sugar. Exemplary nucleosides include adenosine, guanosine, cytidine, uridine and thymidine. The term "nucleotide" refers to a nucleoside having one or more phosphate groups joined in ester linkages to the sugar moiety. Exemplary nucleotides include nucleoside monophosphates, diphosphates and triphosphates. The terms "polynucleotide" and "nucleic acid molecule" are used interchangeably herein and refer to a polymer of nucleotides joined together by a phosphodiester linkage between 5' and 3' carbon atoms.

25       The term "mutation" refers to a substitution, addition, or deletion of a nucleotide within a gene sequence resulting in aberrant production (*e.g.*, misregulated production) of the protein encoded by the gene sequence. A "gain-of-function" mutation is a

mutation that results in production of a protein having aberrant function as compared to the wild-type or normal protein encoded by a gene sequence.

The term “pharmaceutical composition” as used herein, refers to an agent formulated with one or more compatible solid or liquid filler diluents or encapsulating substances which are suitable for administration to a human or lower animal.

A gene “involved” in a disorder includes a gene, the normal or aberrant expression or function of which effects or causes a disease or disorder or at least one symptom of said disease or disorder.

The phrase “examining the function of a gene in a cell or organism” refers to examining or studying the expression, activity, function or phenotype arising therefrom.

Various methodologies of the instant invention include a step that involves comparing a value, level, feature, characteristic, property, *etc.* to a “suitable control”, referred to interchangeably herein as an “appropriate control”. A “suitable control” or “appropriate control” is any control or standard familiar to one of ordinary skill in the art useful for comparison purposes. In one embodiment, a “suitable control” or “appropriate control” is a value, level, feature, characteristic, property, *etc.* determined prior to performing an RNAi methodology, as described herein. For example, a transcription rate, mRNA level, translation rate, protein level, biological activity, cellular characteristic or property, genotype, phenotype, *etc.* can be determined prior to introducing an RNAi agent of the invention into a cell or organism. In another embodiment, a “suitable control” or “appropriate control” is a value, level, feature, characteristic, property, *etc.* determined in a cell or organism, *e.g.*, a control or normal cell or organism, exhibiting, for example, normal traits. In yet another embodiment, a “suitable control” or “appropriate control” is a predefined value, level, feature, characteristic, property, *etc.*

The term “upstream” refers to nucleotide sequences that precede, *e.g.*, are on the 5’ side of, a reference sequence.

The term “downstream” refers to nucleotide sequences that follow, *e.g.*, are on the 3’ side of, a reference sequence.

The terms used herein are not intended to be limiting of the invention.

## II. shRNA-encoding Nucleic Acids

Preferred constructs of the instant invention include nucleic acid sequences or molecules that encode (*i.e.*, generate) shRNA molecules. The requisite elements of a shRNA-encoding nucleic acid sequence or molecule include a first portion and a second portion, having sequences such that the RNA sequences encoded by said portions have sufficient complementarity to anneal or hybridize to form a duplex or double-stranded stem portion. The two portions need not be fully or perfectly complementary. The first and second "stem-encoding" portions are connected by a portion having a sequence that, when encoded, has insufficient sequence complementarity to anneal or hybridize to other portions of the shRNA. This latter portion is referred to as a "loop-encoding" portion in the shRNA-encoding nucleic acid sequences or molecules. The shRNA-encoding nucleic acid sequences or molecules are transcribed to generate shRNAs. shRNAs can also include one or more bulges, *i.e.*, extra nucleotides that create a small nucleotide "loop" in a portion of the stem, for example a one-, two- or three-nucleotide loop. The encoded stem portions can be the same length, or one portion can include an overhang of, for example, 1-5 nucleotides. The overhanging nucleotides can include, for example, uracils (Us), *e.g.*, all Us. Such Us are notably encoded by thymidines (Ts) in the shRNA-encoding DNA which signal the termination of transcription.

One strand of the stem portion of the encoded shRNA is further sufficiently complementary (*e.g.*, antisense) to a target RNA (*e.g.*, mRNA) sequence to mediate degradation or cleavage of said target RNA *via* RNA interference (RNAi). The antisense portion can be on the 5' or 3' end of the stem. The stem-encoding portions of a shRNA-encoding nucleic acid (or stem portion of a shRNA) are preferably about 15 to about 50 nucleotides in length. When used in mammalian cells, the length of the stem portions should be less than about 30 nucleotides to avoid provoking non-specific responses like the interferon pathway. In non-mammalian cells, the stem can be longer than 30 nucleotides. In fact, a stem portion can include much larger sections complementary to the target mRNA (up to, and including the entire mRNA). The loop portion in the shRNA (or loop-encoding portion in the encoding DNA) can be about 2 to about 20 nucleotides in length, *i.e.*, about 2, 3, 4, 5, 6, 7, 8, 9, or more, *e.g.*, 15 or 20, or more nucleotides in length. A preferred loop consists of or comprises a "tetraloop"



sequences. Exemplary tetraloop sequences include, but are not limited to, the sequences GNRA, where N is any nucleotide and R is a purine nucleotide, GGGG, and UUUU.

The sequence of the antisense portion of a shRNA can be designed by selecting an 18, 19, 20, 21 nucleotide, or longer, sequence from within the target RNA (*e.g.*, mRNA), for example, from a region 100 to 200 or 300 nucleotides upstream or downstream of the start of translation. In general, the sequence can be selected from any portion of the target RNA (*e.g.*, mRNA) including the 5' UTR (untranslated region), coding sequence, or 3' UTR. This sequence can optionally follow immediately after a region of the target gene containing two adjacent AA nucleotides. The last two nucleotides of the nucleotide sequence can be selected to be UU. shRNAs so generated are processed under appropriate conditions (*e.g.*, in an appropriate *in vitro* reaction or in a cell) by RNAi machinery (*i.e.*, Dicer and/or RISC complexes) to generate siRNAs. shRNAs can be synthesized exogenously or can be transcribed *in vivo* from an RNA polymerase (*e.g.*, a Pol II or Pol III polymerase), thus permitting the construction of continuous cell lines or transgenic animals in which the desired gene silencing is stable and heritable.

In certain aspects of the invention, it may be important to detect the generation or expression of shRNAs, target mRNAs and/or the gene products encoded by said target RNAs. The detection methods used herein include, for example, cloning and sequencing, ligation of oligonucleotides, use of the polymerase chain reaction and variations thereof (*e.g.*, a PCR that uses 7-deaza GTP), use of single nucleotide primer-guided extension assays, hybridization techniques using target-specific oligonucleotides that can be shown to preferentially bind to complementary sequences under given stringency conditions, and sandwich hybridization methods.

Sequencing may be carried out with commercially available automated sequencers utilizing labeled primers or terminators, or using sequencing gel-based methods. Sequence analysis is also carried out by methods based on ligation of oligonucleotide sequences which anneal immediately adjacent to each other on a target DNA or RNA molecule (Wu and Wallace, *Genomics* 4: 560-569 (1989); Landren *et al.*, *Proc. Natl. Acad. Sci.* 87: 8923-8927 (1990); Barany, F., *Proc. Natl. Acad. Sci.* 88: 189-193 (1991)). Ligase-mediated covalent attachment occurs only when the oligonucleotides are correctly base-paired. The Ligase Chain Reaction (LCR), which

utilizes the thermostable Taq ligase for target amplification, is particularly useful for interrogating late onset diabetes mutation loci. The elevated reaction temperatures permits the ligation reaction to be conducted with high stringency (Barany, F., PCR Methods and Applications 1: 5-16 (1991)).

5           The hybridization reactions may be carried out in a filter-based format, in which the target nucleic acids are immobilized on nitrocellulose or nylon membranes and probed with oligonucleotide probes. Any of the known hybridization formats may be used, including Southern blots, slot blots, "reverse" dot blots, solution hybridization, solid support based sandwich hybridization, bead-based, silicon chip-based and  
10   microtiter well-based hybridization formats.

Detection oligonucleotide probes range in size between 10-1,000 bases. In order to obtain the required target discrimination using the detection oligonucleotide probes, the hybridization reactions are generally run between 20°-60°C., and most preferably between 30°-50°C. As known to those skilled in the art, optimal discrimination between  
15   perfect and mismatched duplexes is obtained by manipulating the temperature and/or salt concentrations or inclusion of formamide in the stringency washes.

Detection of proteins may be carried out using specific antibodies, *e.g.*, monoclonal or polyclonal antibodies, or fragments thereof.

Preferred detection reagents are labeled, *e.g.*, fluorescents, coloro-metrically or  
20   radio-iso-typically labeled to facilitate visulalization and/or quantitation.

### III.   Regulatable Systems

#### 25       A. Regulation of shRNA Expression by Site-Specific Recombinase System

The present invention provides a regulatory system which utilizes a site specific recombinase system to regulate shRNA expression in eukaryotic cells. In particular, this invention provides recombinase-regulated shRNA expression constructs comprising an shRNA encoding nucleic acid sequence and additionally comprising two recombinase-  
30   sensitive elements in an appropriate orientation such that all or a portion of the construct is excisable upon exposure to Cre. In one embodiment, the shRNA encoding nucleic acid sequence is under the control of a Pol III promoter, *e.g.*, U6 promoter. In another

embodiment, the shRNA encoding nucleic acid sequence is under the control of a Pol II promoter, e.g., Ubiquitin C promoter (UbCP). The construct may further comprise a marker protein encoding nucleic acid sequence in order to follow shRNA expression. The marker protein can be any marker protein commonly known in the art, e.g., red  
5 fluorescent protein or green fluorescent protein.

The present invention utilizes a site specific recombinase system, e.g., the Cre/lox system of bacteriophage P1, which is widely used to engineer gene recombination in mice and plants. Other different site specific recombinase systems that may be used include the FLP/FRT system of yeast (see e.g., O'Gormen *et al.* (1991)  
10 Science 251:1351), the Gin recombinase of phage Mu, the Pin recombinase of *E. coli*, and the R/RS system of the pSR1 plasmid. In the Cre/lox system, a recombinase protein, e.g., the Cre recombinase protein, will interact specifically with its respective site-specific recombination sequence, known as lox sites, to invert or excise the intervening sequences.

15 Cre is a 38 kDa recombinase protein from bacteriophage P1 which mediates intramolecular (excisive or inversional) and intermolecular (integrative) site specific recombination between loxP sites (see review article by Brian Sauer in Methods of Enzymology; 1993, Vol. 225, 890-900). The constructs of the instant invention feature loxP sites placed in an orientation such that excisive site specific recombination occurs.  
20 A loxP site (locus of crossing over) consists of two 13 bp inverted repeats separated by an 8 bp asymmetric spacer region. Preferably, the two loxP sites are placed at least about 10, 50, 100, 150, 200, 300, 400, 500 or more nucleotides apart. More preferably, the two loxP sites are placed at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 nucleotides apart. Even more preferably, the two loxP sites are placed at least 60, 65,  
25 70, 75, 80, 85, 90, 95 or 100 nucleotides apart. Most preferably, the two loxP sites are placed at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 or more nucleotides apart.

The nucleotide sequence of the insert repeats and the spacer region of LoxP is as follows: ATAACTTCGTATA ATGTATGC TATACGAAGTTAT. Other suitable lox sites include LoxB, LoxC2, LoxL and LoxR sites which are nucleotide sequences  
30 isolated from *E. coli*. These sequences are disclosed and described by Hoess *et al.*, Proc. Natl. Acad. Sci. USA 79:3398 (1982), the entire disclosure of which is hereby incorporated herein by reference. Preferably, the lox site is LoxP.

One molecule of Cre binds per inverted repeat or two Cre molecules line up at one loxP site. The recombination occurs in the asymmetric spacer region. Those 8 bases are also responsible for the directionality of the site. Two loxP sequences in direct orientation dictate excision of the intervening DNA between the sites leaving one loxP site behind.

In particular, recombination between lox sites in the same orientation results in a deletion of the DNA segment located between the two lox sites and a connection between the resulting ends of the original DNA molecule. The deleted DNA segment forms a circular molecule of DNA. The original DNA molecule and the resulting circular molecule each contain a single lox site.

#### B. Regulation of shRNA Expression by Tetracycline or Analogues Thereof

The present invention provides a regulatory system which utilizes components of the Tet repressor/operator/inducer system of prokaryotes to regulate shRNA expression in eukaryotic cells. In particular, this invention provides tetracycline-regulated shRNA expression constructs comprising an shRNA encoding nucleic acid sequence linked to one or more *tet* operator sequences. In one embodiment, the shRNA encoding nucleic acid sequence is under the control of a Pol II promoter, e.g., Ubiquitin C promoter (UbCP). However, it will be understood that a Pol III promoter is also contemplated.

The constructs may additionally comprise nucleotide sequences encoding a tetracycline transcriptional inhibitor or tetracycline transcriptional activator. In one embodiment, the nucleotide sequences encoding a tetracycline transcriptional inhibitor or activator are under the transcriptional control of the same Pol II promoter, e.g., Ubiquitin C promoter. In another embodiment, the nucleotide sequences encoding a tetracycline transcriptional inhibitor or activator are under the transcriptional control of an independent Pol II promoter. Alternatively, the tetracycline inhibitor or activator may be present and introduced into host cells on a second, distinct expression vector or may be stably integrated into the host cell's genome. The tetracycline-regulated shRNA expression constructs are useful in methods of modulating or regulating shRNA expression in a highly controlled manner.

This invention provides expression constructs encoding the shRNA operatively linked to one or more *tet* operator sequences, and in certain embodiments, additionally

encoding the transcriptional repressor or activator. In a preferred embodiment, the shRNA is operatively linked to at least two or more *tet* operator sequences. The invention further provides recombinant expression vectors containing these constructs in a form suitable for expression of the encoded shRNA and transcriptional repressor or  
5 activator in a host cell. The invention still further provides host cells into which a recombinant expression vector of the invention has been introduced. Thus, an shRNA is expressed in these host cells. The host cell can be, for example, a mammalian cell (e.g., a human cell), a yeast cell, a fungal cell or an insect cell. Moreover, the host cell can be a fertilized non-human oocyte, in which case the host cell can be used to create a  
10 transgenic organism having cells that express the shRNA. Still further, the recombinant expression vector can be designed to allow homologous recombination between the nucleic acid encoding the shRNA and the genomic DNA in a host cell. Such homologous recombination vectors can be used to create homologous recombinant animals that express an shRNA of the invention.

15 To regulate transcription of the *tet* operator-linked shRNA in these host cells, the concentration of Tc (or analogue thereof) in contact with the host cell is altered. For example, when a tetracycline transcriptional repressor binds to *tet* operator sequences in the absence of Tc, the concentration of Tc in contact with the cells is increased to thereby induce transcription of the *tet* operator-linked shRNA. Alternatively, when the  
20 tetracycline transcriptional repressor binds to *tet* operator sequences in the presence of Tc, the concentration of Tc in contact with the cells is decreased to thereby induce transcription of the *tet* operator-linked shRNA.

In one aspect of the invention, shRNA expression is controlled by using a tetracycline transcriptional repressor protein that binds to *tet* operator sequences. Such  
25 tetracycline-based regulatory systems are well described and will be well known to one of skill in the art. In one embodiment, shRNA expression can be controlled by using the tetracycline transcriptional repressor. Alternatively, shRNA expression can be controlled by using a transcriptional inhibitor fusion protein. A transcriptional inhibitor fusion protein may be composed of at least two polypeptides, a first polypeptide that  
30 binds to *tet* operator sequences, e.g., a tetracycline transcriptional repressor, and a heterologous second polypeptide that directly or indirectly inhibits transcription in eukaryotic cells. The heterologous second polypeptide is derived from a different

protein than the first polypeptide. Because the fusion proteins include a eukaryotic transcriptional silencer domain, they are anticipated to be more efficient at repressing transcription in eukaryotic cells than is a Tet Repressor alone.

Where a transcriptional inhibitor fusion protein is employed, in one embodiment  
5 the first polypeptide of the inhibitor fusion protein binds to *tet* operator sequences in the absence but not the presence of tetracycline (Tc) or an analogue thereof (e.g., the first polypeptide is preferably a Tet repressor). Thus, in the absence of tetracycline (or Tc analogue), this fusion protein binds to *tet* operator sequences operatively linked to shRNA encoding sequence, thereby inhibiting transcription of the shRNA. In another  
10 embodiment, the first polypeptide binds to *tet* operator sequences in the presence but not the absence of tetracycline (e.g., the first polypeptide is preferably a mutated Tet repressor). In the presence of tetracycline (or Tc analogue), this fusion protein binds to *tet* operator sequences operatively linked to an shRNA encoding sequence, thereby inhibiting transcription of the shRNA. The second polypeptide can be a transcriptional  
15 "silencer" domain from a protein such as the v-erbA oncogene product, the Drosophila Krueppel protein, the retinoic acid receptor alpha, the thyroid hormone receptor alpha, the yeast Ssn6/Tup1 protein complex, the Drosophila protein even-skipped, SIR1, NeP1, the Drosophila dorsal protein, TSF3, SFI, the Drosophila hunchback protein, the Drosophila knirps protein, WT1, Oct-2.1, the Drosophila engrailed protein, E4BP4 or  
20 ZF5. The fusion protein may further comprise additional polypeptides, such as a third polypeptide which promotes transport of the fusion protein into a cell nucleus (i.e., a nuclear transport amino acid sequence).

These methods can be used to regulate basal, constitutive or tissue-specific transcription and to induce transcription of a *tetO*-linked shRNA of interest. For  
25 example, an shRNA of interest that is operatively linked to one or more *tetO* sequences (e.g., two *tetO* sequences), and optionally additional positive regulatory elements (e.g., constitutive or tissue-specific enhancer sequences), will be transcribed in host cells at a level that is primarily determined by the strength of the positive regulatory elements in the host cell. Moreover, an shRNA of interest that is operatively linked to *tetO*  
30 sequences and only a minimal promoter sequence may exhibit varying degrees of basal level transcription depending on the host cell or tissue and/or the site of integration of the sequence. In a host cell containing such an shRNA encoding sequence and

expressing a tetracycline transcriptional repressor or inhibitor fusion protein, transcription of the shRNA sequence can be upregulated in a controlled manner by altering (e.g., increasing) the concentration of Tc (or analogue) in contact with the host cell. For example, when the tetracycline transcriptional repressor or inhibitor fusion  
5 protein binds to *tetO* in the absence of Tc, the concentration of Tc in contact with the host cell is increased to induce expression of the shRNA. For example, Tc is added to the culture medium of a host cell or Tc is administered to a host organism to repress shRNA expression. Alternatively, when the inhibitor fusion protein binds to *tetO* in the presence of Tc, the concentration of Tc in contact with the host cell is decreased to  
10 induce expression of the shRNA.

The tetracycline-regulated shRNA expression constructs described herein can regulate a *tetO*-linked shRNA in which the *tetO* sequences are positioned 5' of a minimal promoter sequence. Furthermore, tetracycline-regulated shRNA expression constructs described herein can regulate a *tetO*-linked shRNA in which *tetO*-linked sequences are  
15 located 3' of the promoter sequence but 5' of the transcription start site. Still further, tetracycline-regulated shRNA expression constructs described herein can regulate a *tetO*-linked shRNA in which *tetO*-linked sequences are located 3' of the transcription start site.

It will be understood that, in the compositions and methods of the instant  
20 invention, shRNA expression can also be controlled by using a tetracycline transcriptional activator fusion protein. Such systems are well described and will be known to one of skill in the art. In a host cell which carries nucleic acid encoding a transcriptional activator fusion protein and an shRNA encoding nucleotide sequence operatively linked to the *tet* operator sequence (either on the same vector or two distinct  
25 vectors), high level transcription of the shRNA encoding nucleotide sequence operatively linked to the *tet* operator sequence(s) does not occur in the absence of the inducing agent, e.g., tetracycline or analogues thereof. The level of basal transcription of the nucleotide sequence may vary depending upon the host cell and site of integration of the sequence, but is generally quite low or even undetectable in the absence of Tc. In  
30 order to induce transcription in a host cell, the host cell is contacted with tetracycline or a tetracycline analogue. Accordingly, another aspect of the invention pertains to methods for stimulating transcription of an shRNA encoding nucleotide sequence

operatively linked to one or more *tet* operator sequences in a host cell or animal which expresses a transcriptional activator fusion protein. The methods involve contacting the cell with tetracycline or a tetracycline analogue or administering tetracycline or a tetracycline analogue to a subject containing the cell.

- 5           In addition to regulating shRNA expression using either a transcriptional activator or inhibitor alone, the two types of proteins can be used in combination to allow for both positive and negative regulation of expression of one or more shRNA encoding sequences in a host cell. Thus, a transcriptional inhibitor protein that binds to *tetO* either (i) in the absence, but not the presence, of Tc, or (ii) in the presence, but not  
10 the absence, of Tc, can be used in combination with a transcriptional activator protein that binds to *tetO* either (i) in the absence, but not the presence, of Tc, or (ii) in the presence, but not the absence, of Tc.

- For example, expression of a *tetO*-linked shRNA encoding sequence in a host cell is regulated in both a negative and positive manner by the combination of an  
15 inhibitor fusion protein that binds to *tetO* in the absence, but not the presence, of tetracycline or analogue thereof (referred to as a tetracycline controlled silencing domain, or tSD) and an activator fusion protein that binds to *tetO* in the presence, but not the absence, of tetracycline or analogue thereof (referred to as a reverse tetracycline controlled transactivator, or rtTA). In addition to *tetO* sequences, the shRNA encoding  
20 sequence is linked to a promoter (e.g., a Pol II promoter, e.g., a Ubiquitin C promoter), and may optionally contain other positive regulatory elements (e.g., enhancer sequences) that contribute to basal level, constitutive transcription of the shRNA in the host cell. Binding of tSD to the *tetO* sequences in the absence of tetracycline or analogue (e.g., doxycycline) inhibits the basal constitutive transcription of the shRNA encoding  
25 sequence, thus keeping the shRNA encoding sequence in a repressed state until shRNA expression is desired. When expression is desired, the concentration of tetracycline or analogue (e.g., doxycycline) in contact with the host cell increased. Upon addition of the drug, tSD loses the ability to bind to *tetO* sequences whereas the previously unbound rtTA acquires the ability to bind to *tetO* sequences. The resultant binding of rtTA to the  
30 *tetO* sequences linked to the shRNA encoding sequence thus stimulates transcription of the shRNA. The level of expression may be controlled by the concentration of tetracycline or analogue, the type of Tc analogue used, the duration of induction, etc., as



described previously herein. It will be appreciated that the reverse combination of fusion proteins (i.e., the inhibitor binds in the presence but not the absence of the drug and the activator binds in the absence but not the presence of the drug) can also be used. In this case, expression of the shRNA encoding sequence is kept repressed by contacting  
5 the host cell with the drug (e.g., culture with Tc or analogue) and expression is activated by removal of the drug.

The term "tetracycline analogue" is intended to include compounds which are structurally related to tetracycline and which bind to the Tet repressor with a  $K_a$  of at least about  $10^6 \text{ M}^{-1}$ . Preferably, the tetracycline analogue binds with an affinity of about  
10  $10^9 \text{ M}^{-1}$  or greater. Examples of such tetracycline analogues include, but are not limited to, anhydrotetracycline, doxycycline, chlorotetracycline, oxytetracycline and others disclosed by Hlavka and Boothe, "The Tetracyclines," in *Handbook of Experimental Pharmacology* 78, R.K. Blackwood et al. (eds.), Springer-Verlag, Berlin-New York, 1985; L.A. Mitscher, "The Chemistry of the Tetracycline Antibiotics", *Medicinal*  
15 *Research* 9, Dekker, New York, 1978; Noyee Development Corporation, "Tetracycline Manufacturing Processes" *Chemical Process Reviews*, Park Ridge, NJ, 2 volumes, 1969; R.C. Evans, "The Technology of the Tetracyclines", *Biochemical Reference Series 1*, Quadrangle Press, New York, 1968; and H.F. Dowling, "Tetracycline", *Antibiotic Monographs*, no. 3, Medical Encyclopedia, New York, 1955. Preferred Tc analogues  
20 for high level stimulation of transcription are anhydrotetracycline and doxycycline. A Tc analogue can be chosen which has reduced antibiotic activity compared to Tc. Examples of such Tc analogues are anhydrotetracycline and epioxytetracycline.

To induce shRNA expression in a cell *in vitro*, the cell is contacted with Tc or a Tc analogue by culturing the cell in a medium containing the compound. When  
25 culturing cells *in vitro* in the presence of Tc or Tc analogue, a preferred concentration range for the inducing agent is between about 10 and about 1000 ng/ml. Tc or a Tc analogue can be directly added to media in which cells are already being cultured, or more preferably for high levels of shRNA expression, cells are harvested from Tc-free media and cultured in fresh media containing Tc, or an analogue thereof.

30 To induce shRNA expression *in vivo*, cells within in a subject are contacted with Tc or a Tc analogue by administering the compound to the subject. The term "subject" is intended to include humans and other non-human mammals including monkeys, cows,

goats, sheep, dogs, cats, rabbits, rats, mice, and transgenic and homologous recombinant species thereof. Furthermore, the term "subject" is intended to include plants, such as transgenic plants. When the inducing agent is administered to a human or animal subject, the dosage is adjusted to preferably achieve a serum concentration between  
5 about 0.05 and 1.0 µg/ml. Tc or a Tc analogue can be administered to a subject by any means effective for achieving an *in vivo* concentration sufficient for shRNA induction. Examples of suitable modes of administration include oral administration (e.g., dissolving the inducing agent in the drinking water), slow release pellets and implantation of a diffusion pump. To administer Tc or a Tc analogue to a transgenic  
10 plant, the inducing agent can be dissolved in water administered to the plant.

The ability to use different Tc analogues as inducing agents in this system allows for modulate the level of expression of a *tet* operator-linked nucleotide sequence. As demonstrated in Example 2, anhydrotetracycline and doxycycline have been found to be strong inducing agents. The increase in transcription of the target sequence is typically  
15 as high as 1000- to 2000-fold, and induction factors as high as 20,000 fold can be achieved. Tetracycline, chlorotetracycline and oxytetracycline have been found to be weaker inducing agents, i.e., the increase in transcription of a target sequence is in the range of about 10-fold. Thus, an appropriate tetracycline analogue is chosen as an inducing agent based upon the desired level of induction of shRNA expression. It is also  
20 possible to change the level of shRNA expression in a host cell or animal over time by changing the Tc analogue used as the inducing agent. For example, there may be situations where it is desirable to have a strong burst of shRNA expression initially and then have a sustained lower level of shRNA expression. Accordingly, an analogue which stimulates a high levels of transcription can be used initially as the inducing agent  
25 and then the inducing agent can be switched to an analogue which stimulates a lower level of transcription. Moreover, when regulating the expression of multiple nucleotide sequences (e.g., when one sequence is regulated by a one of class *tet* operator sequence(s) and the other is regulated by another class of *tet* operator sequence(s), as described above in Section III, Part C, above), it may be possible to independently vary  
30 the level of expression of each sequence depending upon which transcriptional activator fusion protein is used to regulate transcription and which Tc analogue(s) is used as the inducing agent. Different transcriptional activator fusion proteins are likely to exhibit

different levels of responsiveness to Tc analogues. The level of induction of shRNA expression by a particular combination of transcriptional activator fusion protein and inducing agent (Tc or Tc analogue) can be determined by techniques described herein, (e.g., see Example 2). Additionally, the level of shRNA expression can be modulated by  
5 varying the concentration of the inducing agent. Thus, the expression system of the invention provides a mechanism not only for turning shRNA expression on or off, but also for "fine tuning" the level of shRNA expression at intermediate levels depending upon the type and concentration of inducing agent used.

#### 10 IV. Constructs/Transgene

A construct is a recombinant nucleic acid, generally recombinant DNA, generated for the purpose of the expression of a specific nucleotide sequence(s), or is to be used in the construction of other recombinant nucleotide sequences. A transgene is a  
15 construct that has been or is designed to be incorporated into a cell, particularly a mammalian cell, that in turn becomes or is incorporated into a living animal such that the construct containing the nucleotide sequence is expressed (*i.e.*, the mammalian cell is transformed with the transgene). The transgene may include a sequence (*e.g.*, a shRNA-encoding sequence) that is endogenous or exogenous to the transgenic animal. A transgene may be present as an extrachromosomal element in some or all of the cells of  
20 a transgenic animal or, preferably, stably integrated into some or all of the cells, more preferably into the germline DNA of the animal (*i.e.*, such that the transgene is transmitted to all or some of the animal's progeny), thereby directing expression of the product of the transgene in one or more cell types or tissues of the transgenic animal. Unless otherwise indicated, it will be assumed that a transgenic animal comprises stable  
25 changes to the chromosomes of germline cells. In a preferred embodiment, the transgene is present in the genome at a site such that it does not interfere with gene expression.

Such transgenic animals are created by introducing a transgenic construct of the invention into its genome using methods and vectors as described herein.

30 A transgenic construct of the invention includes the encoding sequence operably linked to an appropriate promoter sequence. The transgene optionally includes enhancer

sequences and other non-coding sequences (for example, intron and/or 5' or 3' untranslated sequences).

## V. Vectors and Host Cells

5 Another aspect of the invention pertains to vectors, preferably expression vectors, containing a construct of the invention (or a portion thereof). As used herein, the term "vector" refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double stranded DNA loop into which additional DNA segments can be  
10 ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (*e.g.*, non-episomal mammalian vectors) are integrated into the genome of a host cell upon  
15 introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "expression vectors".

In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. Accordingly, in one embodiment, an expression vector of  
20 the invention is a plasmid. In the present specification, "plasmid" and "vector" can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (*e.g.*, replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions. Thus, in one embodiment, an  
25 expression vector of the invention is a viral-based vector. For example, replication defective retroviruses, adenoviruses and adeno-associated viruses can be used. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other  
30 standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines include  $\psi$ Crip,  $\psi$ Cre,  $\psi$ 2 and  $\psi$ Am. The genome of adenovirus can be manipulated such that it encodes and expresses a regulatable shRNA construct, as described herein, but is inactivated in terms of its ability to replicate in a normal lytic

viral life cycle. See for example Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155.

Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Alternatively, an adeno-associated virus vector such as that described in Tratschin et al. (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to express a transactivator fusion protein. In a particular embodiment of the invention, an expression vector is not a viral vector.

The vectors of the invention comprise a shRNA-encoding nucleic acid operatively linked to one or more regulatory sequences (e.g., promoter sequences, e.g., Pol II or Pol III promoter sequences). The phrase "operably linked" is intended to mean that the nucleotide sequence of interest (e.g., the shRNA-encoding sequence) is linked to the regulatory sequence(s) in a manner which allows for expression of the nucleotide sequence (e.g., in an *in vitro* transcription/translation system or in a host cell when the vector is introduced into the host cell). The term "regulatory sequence" is intended to include promoters, enhancers and other expression control elements, such as transcription termination signals (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). Regulatory sequences include those which direct constitutive expression of a nucleotide sequence in many types of host cell and those which direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). Other elements included in the design of a particular expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc.

The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein.

The vectors described herein can be introduced into cells or tissues by any one of a variety of known methods within the art. Such methods are described for example in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, New York (1992), which is hereby incorporated by reference. See, also, Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons, Baltimore, Md.(1989); Hitt et al., "Construction and propagation of human adenovirus

vectors," in *Cell Biology: A Laboratory Handbook*, Ed. J. E. Celis., Academic Press. 2<sup>nd</sup> Edition, Volume 1, pp: 500-512, 1998; Hitt *et al.*, "Techniques for human adenovirus vector construction and characterization," in *Methods in Molecular Genetics*, Ed. K. W. Adolph, Academic Press, Orlando, Fla., Volume 7B, pp:12-30, 1995; Hitt, *et al.*, "Construction and propagation of human adenovirus vectors," in *Cell Biology: A Laboratory Handbook*, Ed. J. E. Celis. Academic Press. pp:479-490, 1994, also hereby incorporated by reference. The methods include, for example, stable or transient transfection, lipofection, electroporation and infection with recombinant viral vectors. The term "transfecting" or "transfection" is intended to encompass all conventional techniques for introducing nucleic acid into host cells, including calcium phosphate co-precipitation, DEAE-dextran-mediated transfection, lipofection, electroporation and microinjection. Suitable methods for transfecting host cells can be found in Sambrook *et al.* (*Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> Edition, Cold Spring Harbor Laboratory press (1989)), and other laboratory textbooks.

The number of host cells transformed with a nucleic acid of the invention will depend, at least in part, upon the type of recombinant expression vector used and the type of transfection technique used. Nucleic acid can be introduced into a host cell transiently, or more typically, for long term regulation of gene expression, the nucleic acid is stably integrated into the genome of the host cell or remains as a stable episome in the host cell. Plasmid vectors introduced into mammalian cells are typically integrated into host cell DNA at only a low frequency. In order to identify these integrants, a gene that contains a selectable marker (e.g., drug resistance) is generally introduced into the host cells along with the nucleic acid of interest. Preferred selectable markers include those which confer resistance to certain drugs, such as G418 and hygromycin. Selectable markers can be introduced on a separate plasmid from the nucleic acid of interest or, are introduced on the same plasmid. Host cells transfected with a nucleic acid of the invention (e.g., a recombinant expression vector) and a gene for a selectable marker can be identified by selecting for cells using the selectable marker. For example, if the selectable marker encodes a gene conferring neomycin resistance, host cells which have taken up nucleic acid can be selected with G418. Cells that have incorporated the selectable marker gene will survive, while the other cells die.

Nucleic acid encoding a regulatable shRNA of the invention can be introduced into eukaryotic cells growing in culture *in vitro* by conventional transfection techniques (e.g., calcium phosphate precipitation, DEAE-dextran transfection, electroporation etc.). Nucleic acid can also be transferred into cells *in vivo*, for example by application of a delivery mechanism suitable for introduction of nucleic acid into cells *in vivo*, such as

5 retroviral vectors (see e.g., Ferry, N et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; and Kay, M.A. et al. (1992) *Human Gene Therapy* 3:641-647), adenoviral vectors (see e.g., Rosenfeld, M.A. (1992) *Cell* 68:143-155; and Herz, J. and Gerard, R.D. (1993) *Proc. Natl. Acad. Sci. USA* 90:2812-2816), receptor-mediated DNA uptake (see e.g.,

10 Wu, G. and Wu, C.H. (1988) *J. Biol. Chem.* 263:14621; Wilson et al. (1992) *J. Biol. Chem.* 267:963-967; and U.S. Patent No. 5,166,320), direct injection of DNA (see e.g., Acsadi et al. (1991) *Nature* 332: 815-818; and Wolff et al. (1990) *Science* 247:1465-1468) or particle bombardment (see e.g., Cheng, L. et al. (1993) *Proc. Natl. Acad. Sci. USA* 90:4455-4459; and Zelenin, A.V. et al. (1993) *FEBS Letters* 315:29-32). Thus, for

15 gene therapy purposes, cells can be modified *in vitro* and administered to a subject or, alternatively, cells can be directly modified *in vivo*.

Another aspect of the invention pertains to host cells into which a host construct of the invention has been introduced, *i.e.*, a "recombinant host cell." It is understood that the term "recombinant host cell" refers not only to the particular subject cell but to

20 the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

A host cell can be any prokaryotic or eukaryotic cell, although eukaryotic cells

25 are preferred. Exemplary eukaryotic cells include mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.

The host cells of the invention can also be used to produce nonhuman transgenic animals. The nonhuman transgenic animals can be used in screening assays designed to

30 identify agents or compounds, *e.g.*, drugs, pharmaceuticals, *etc.*, which are capable of ameliorating detrimental symptoms of selected disorders, such as disease and disorders

associated with mutant or aberrant gene expression, gain-of-function mutants and neurological diseases and disorders.

The present invention is also not limited to the use of the cell types and cell lines used herein. Cells from different tissues or different species (human, mouse, *etc.*) are  
5 also useful in the present invention.

## VI. Construction of Transgenic Animals

In one aspect, the present invention provides a non-human animal whose genome contains a shRNA-encoding construct or transgene of the invention. The present  
10 invention further provides methods for making a transgenic non-human animal whose genome contains a shRNA-encoding construct or transgene of the invention.

The transgenic animal used in the methods of the invention can be, *e.g.*, a mammal, a bird, a reptile or an amphibian. Suitable mammals for uses described herein include: rodents; ruminants; ungulates; domesticated mammals; and dairy animals.  
15 Preferred animals include: rodents, goats, sheep, camels, cows, pigs, horses, oxen, llamas, chickens, geese, and turkeys. In a preferred embodiment, the non-human animal is a mouse.

Various methods of making transgenic animals are known in the art (see, *e.g.*, Watson, J. D., *et al.*, "The Introduction of Foreign Genes Into Mice," in *Recombinant DNA*, 2d Ed., W. H. Freeman & Co., New York (1992), pp. 255-272; Gordon, J. W., *Intl. Rev. Cytol.* 115:171-229 (1989); Jaenisch, R., *Science* 240: 1468-1474 (1989); Rossant, J., *Neuron* 2: 323-334 (1990)). An exemplary protocol for the production of a transgenic pig can be found in White and Yannoutsos, *Current Topics in Complement Research: 64th Forum in Immunology*, pp. 88-94; US Patent No. 5,523,226; US Patent  
20 No. 5,573,933; PCT Application WO93/25071; and PCT Application WO95/04744. An exemplary protocol for the production of a transgenic rat can be found in Bader and Ganten, *Clinical and Experimental Pharmacology and Physiology*, Supp. 3:S81-S87, 1996. An exemplary protocol for the production of a transgenic cow can be found in *Transgenic Animal Technology, A Handbook*, 1994, ed., Carl A. Pinkert, Academic  
25 Press, Inc. An exemplary protocol for the production of a transgenic sheep can be found in *Transgenic Animal Technology, A Handbook*, 1994, ed., Carl A. Pinkert, Academic Press, Inc. Several exemplary methods are set forth in more detail below.



#### A. Injection into the Pronucleus

Transgenic animals can be produced by introducing a nucleic acid construct according to the present invention into egg cells. The resulting egg cells are implanted  
5 into the uterus of a female for normal fetal development, and animals which develop and which carry the transgene are then backcrossed to create heterozygotes for the transgene. Embryonal target cells at various developmental stages are used to introduce the transgenes of the invention. Different methods are used depending on the stage of development of the embryonal target cell(s). Exemplary methods for introducing  
10 transgenes include, but are not limited to, microinjection of fertilized ovum or zygotes (Brinster, *et al.*, Proc. Natl. Acad. Sci. USA (1985) 82: 4438-4442), and viral integration (Jaenisch R., Proc. Natl. Acad. Sci. USA (1976) 73: 1260-1264; Jahner, *et al.*, Proc. Natl. Acad. Sci. USA (1985) 82: 6927-6931; Van der Putten, *et al.*, (1985) Proc. Natl. Acad. Sci. (USA) 82: 6148-6152). Procedures for embryo manipulation and  
15 microinjection are described in, for example, *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY., 1986, the contents of which are incorporated herein by reference). Similar methods are used for production of other transgenic animals.

In an exemplary embodiment, production of transgenic mice employs the  
20 following steps. Male and female mice, from a defined inbred genetic background, are mated. The mated female mice are previously treated with pregnant mare serum, PMS, to induce follicular growth and human chorionic gonadotropin, hCG, to induce ovulation. Following mating, the female is sacrificed and the fertilized eggs are removed from her uterine tubes. At this time, the pronuclei have not yet fused and it is  
25 possible to visualize them using light microscopy. In an alternative protocol, embryos can be harvested at varying developmental stages, *e.g.* blastocysts can be harvested. Embryos are recovered in a Dulbecco's modified phosphate buffered saline (DPBS) and maintained in Dulbecco's modified essential medium (DMEM) supplemented with 10% fetal bovine serum.

30 Foreign DNA or the recombinant construct (*e.g.* shRNA-encoding construct or transgene) is then microinjected (100-1000 molecules per egg) into a pronucleus. Microinjection of an expression construct can be performed using standard micro

manipulators attached to a microscope. For instance, embryos are typically held in 100 microliter drops of DPBS under oil while being microinjected. DNA solution is microinjected into the male pronucleus. Successful injection is monitored by swelling of the pronucleus. Shortly thereafter, fusion of the pronuclei (a female pronucleus and a male pronucleus) occurs and, in some cases, foreign DNA inserts into (usually) one chromosome of the fertilized egg or zygote. Recombinant ES cells, which are prepared as set forth below, can be injected into blastocysts using similar techniques.

#### B. Embryonic Stem Cells

In another method of making transgenic mice, recombinant DNA molecules (e.g., constructs or transgenes) of the invention can be introduced into mouse embryonic stem (ES) cells. Resulting recombinant ES cells are then microinjected into mouse blastocysts using techniques similar to those set forth in the previous subsection.

ES cells are obtained from pre-implantation embryos and cultured *in vitro* (Evans, M J., *et al.*, Nature 292: 154156 (1981); Bradley, M. O. *et al.*, Nature 309: 255-258 (1984); Gossler, *et al.*, Proc. Natl. Acad. Sci. (USA) 83:9065-9069 (1986); Robertson *et al.*, Nature 322: 445448 (1986)). Any ES cell line that is capable of integrating into and becoming part of the germ line of a developing embryo, so as to create germ line transmission of the targeting construct, is suitable for use herein. For example, a mouse strain that can be used for production of ES cells is the 129J strain. A preferred ES cell line is murine cell line D3 (American Type Culture Collection catalog no. CRL 1934). The ES cells can be cultured and prepared for DNA insertion using methods known in the art and described in Robertson, *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, E.J. Robertson, ed. IRL Press, Washington, D.C., 1987, in Bradley *et al.*, *Current Topics in Devel. Biol.*, 20:357-371, 1986 and in Hogan *et al.*, *Manipulating the Mouse Embryo: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1986, the contents of which are incorporated herein by reference.

The expression construct can be introduced into the ES cells by methods known in the art, e.g., those described in Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2<sup>nd</sup> Ed., ed., Cold Spring Harbor laboratory Press: 1989, the contents of which are incorporated herein by reference. Suitable methods include, but are not limited to,

electroporation, microinjection, and calcium phosphate treatment methods. The foreign DNA (*e.g.* construct or transgene) to be introduced into the ES cell is preferably linear.

After introduction of the expression construct, the ES cells are screened for the presence of the construct. The cells can be screened using a variety of methods. ES cell genomic DNA can be examined directly. For example, the DNA can be extracted from the ES cells using standard methods and the DNA can then be probed on a Southern blot with a probe or probes designed to hybridize specifically to the transgene. The genomic DNA can also be amplified by PCR with probes specifically designed to amplify DNA fragments of a particular size and sequence of the construct or transgene such that, only those cells containing the construct or transgene will generate DNA fragments of the proper size. Where a marker gene is employed in the construct, the cells of the animal can be tested for the presence of the marker gene. For example, where the marker gene is an antibiotic resistance gene, the cells can be cultured in the presence of an otherwise lethal concentration of antibiotic (*e.g.* G418 to select for *neo*). Those cells that survive have presumably integrated the transgene construct. If the marker gene is a gene that encodes an enzyme whose activity can be detected (*e.g.*,  $\beta$ -galactosidase), the enzyme substrate can be added to the cells under suitable conditions, and the enzymatic activity can be analyzed.

#### 20        C.     Implantation

The zygote harboring a recombinant nucleic acid molecule of the invention (*e.g.* construct or transgene) is implanted into a pseudo-pregnant female mouse that was obtained by previous mating with a vasectomized male. In a general protocol, recipient females are anesthetized, paralumbar incisions are made to expose the oviducts, and the embryos are transformed into the ampullary region of the oviducts. The body wall is sutured and the skin closed with wound clips. The embryo develops for the full gestation period, and the surrogate mother delivers the potentially transgenic mice. Finally, the newborn mice are tested for the presence of the foreign or recombinant DNA. Of the eggs injected, on average 10% develop properly and produce mice. Of the mice born, on average one in four (25%) are transgenic for an overall efficiency of 2.5%. Once these mice are bred they transmit the foreign gene in a normal (Mendelian) fashion linked to a mouse chromosome.

#### D. Screening for the Presence of the Transgenic Construct

Transgenic animals can be identified after birth by standard protocols. DNA from tail tissue can be screened for the presence of the transgene construct, *e.g.*, using southern blots and/or PCR. Offspring that appear to be mosaics are then crossed to each other if they are believed to carry the transgene in order to generate homozygous animals. If it is unclear whether the offspring will have germ line transmission, they can be crossed with a parental or other strain and the offspring screened for heterozygosity. The heterozygotes are identified by southern blots and/or PCR amplification of the DNA. The heterozygotes can then be crossed with each other to generate homozygous transgenic offspring. Homozygotes may be identified by southern blotting of equivalent amounts of genomic DNA from mice that are the product of this cross, as well as mice that are known heterozygotes and wild type mice. Probes to screen the southern blots can be designed based on the sequence of the construct or transgene, or a marker gene, or both.

Other means of identifying and characterizing the transgenic offspring are known in the art. For example, western blots can be used to assess the level of expression of a gene targeted for interference by probing with an antibody against the protein encoded by the target gene. Alternatively, an antibody against a marker gene product can be used, when a marker gene is expressed.

#### E. Mice Containing Multiple Transgenes

Transgenic mice expressing shRNAs as described herein can be crossed with mice that harbor additional transgene(s). Mice that are heterozygous or homozygous for shRNA expression can be generated and maintained using standard crossbreeding procedures. A preferred aspect of the invention features crossing mice that express a shRNA construct or transgene regulatable by a recombinase with mice expressing a corresponding recombinase. In a preferred embodiment, mice that express inducible silencing constructs or inducible desilencing constructs, as described herein, are crossed with mice expressing Cre. Such Cre expressing mice are known in the art and are publicly available, for example, from the Jackson Laboratory (Bar Harbor, Maine) or from Taconic.

The invention further pertains to cells derived from transgenic animals. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.

5

## VII. Uses and Methods of the Invention

The methods of the present invention will find great commercial application, for example in biotechnology, drug development and medicine. For example, in biotechnology, the ability to rapidly develop large numbers of transgenic animals with  
10 desired modulation of specific genes will allow for the analysis of gene function and the evaluation of compounds that potentially modulate gene expression, protein function, and are useful in treating a disease or disorder. In particular, by observing the effect of down-regulating specific genes in transgenic animals, the biological function of those genes may be determined, disease models may be established and drug targets may be  
15 validated. In medicine the methods of the invention may be used to treat patients suffering from particular diseases or disorders, for example, neurological diseases or disorders, or to confer immunity or resistance to particular pathogens. For example, specific cells may be infected *in vivo* or *ex vivo* with recombinant retrovirus encoding a siRNA that down-regulates the activity of a gene whose activity is associated with a  
20 particular disease or disorder.

### A. Screening Assays

Cells and/or animals of the present invention may also be suitable for use in methods to identify and/or characterize potential pharmacological agents, *e.g.*  
25 identifying new pharmacological agents from a collection of test substances and/or characterizing mechanisms of action and/or side effects of known pharmacological agents.

Thus, the present invention also relates to a system for identifying and/or characterizing pharmacological agents comprising: (a) a cell (*e.g.*, a eukaryotic cell) or  
30 organism (*e.g.*, a eukaryotic non-human organism) containing a construct or transgene of the invention and (b) a test substance or a collection of test substances wherein pharmacological properties of said test substance or said collection are to be identified

and/or characterized. Optionally, the system as described above can further comprise suitable controls.

Test compounds can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) *Anticancer Drug Des.* 12:145).

Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt *et al.* (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6909; Erb *et al.* (1994) *Proc. Natl. Acad. Sci. USA* 91:11422; Zuckermann *et al.* (1994). *J. Med. Chem.* 37:2678; Cho *et al.* (1993) *Science* 261:1303; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2059; Carrell *et al.* (1994) *Angew. Chem. Int. Ed. Engl.* 33:2061; and in Gallop *et al.* (1994) *J. Med. Chem.* 37:1233.

Libraries of compounds may be presented in solution (*e.g.*, Houghten (1992) *Biotechniques* 13:412-421), or on beads (Lam (1991) *Nature* 354:82-84), chips (Fodor (1993) *Nature* 364:555-556), bacteria (Ladner USP 5,223,409), spores (Ladner USP '409), plasmids (Cull *et al.* (1992) *Proc Natl Acad Sci USA* 89:1865-1869) or on phage (Scott and Smith (1990) *Science* 249:386-390); (Devlin (1990) *Science* 249:404-406); (Cwirla *et al.* (1990) *Proc. Natl. Acad. Sci.* 87:6378-6382); (Felici (1991) *J. Mol. Biol.* 222:301-310); (Ladner *supra.*)).

In a preferred embodiment, the library is a natural product library, *e.g.*, a library produced by a bacterial, fungal, or yeast culture. In another preferred embodiment, the library is a synthetic compound library.

Compounds or agents identified according to such screening assays can be used therapeutically or prophylactically either alone or in combination, for example, with an shRNA of the invention, as described herein.

B. Knockout and/or Knockdown Cells or Organisms

A shRNAs (either known or identified by the methodologies of the present invention) can be used in a functional analysis of the corresponding target RNA (either known or identified by the methodologies of the present invention). Such a functional analysis is typically carried out in eukaryotic cells, or eukaryotic non-human organisms, preferably mammalian cells or organisms and most preferably human cells, *e.g.* cell lines such as HeLa or 293 or rodents, *e.g.* rats and mice. By administering a suitable shRNA molecule, a specific knockout or knockdown phenotype can be obtained in a target cell, *e.g.* in cell culture or in a target organism.

Thus, further subject matter of the invention includes cells (*e.g.*, eukaryotic cells) or organisms (*e.g.*, eukaryotic non-human organisms) exhibiting a target gene-specific knockout or knockdown phenotype resulting from a fully or at least partially deficient expression of at least one endogenous target gene wherein said cell or organism is transfected with or administered, respectively, at least one shRNA, vector comprising DNA encoding said shRNA (or an shRNA precursor) capable of inhibiting the expression of the target gene. It should be noted that the present invention allows a target-specific knockout or knockdown of several different endogenous genes based on the specificity of the shRNA(s) transfected or administered.

Gene-specific knockout or knockdown phenotypes of cells or non-human organisms, particularly of human cells or non-human mammals may be used in analytic procedures, *e.g.* in the functional and/or phenotypical analysis of complex physiological processes such as analysis of gene expression profiles and/or proteomes. Preferably the analysis is carried out by high throughput methods using oligonucleotide based chips.

Using RNAi based knockout or knockdown technologies, the expression of an endogenous target gene may be inhibited in a target cell or a target organism. The endogenous gene may be complemented by an exogenous target nucleic acid coding for the target protein or a variant or mutated form of the target protein, *e.g.* a gene or a DNA, which may optionally be fused to a further nucleic acid sequence encoding a detectable peptide or polypeptide, *e.g.* an affinity tag, particularly a multiple affinity tag.

Variants or mutated forms of the target gene differ from the endogenous target gene in that they encode a gene product which differs from the endogenous gene product on the amino acid level by substitutions, insertions and/or deletions of single or

multiple amino acids. The variants or mutated forms may have the same biological activity as the endogenous target gene. On the other hand, the variant or mutated target gene may also have a biological activity, which differs from the biological activity of the endogenous target gene, *e.g.* a partially deleted activity, a completely deleted activity, an enhanced activity *etc.* The complementation may be accomplished by compressing the polypeptide encoded by the endogenous nucleic acid, *e.g.* a fusion protein comprising the target protein and the affinity tag and the double stranded RNA molecule for knocking out the endogenous gene in the target cell. This compression may be accomplished by using a suitable expression vector expressing both the polypeptide encoded by the endogenous nucleic acid, *e.g.* the tag-modified target protein and the double stranded RNA molecule or alternatively by using a combination of expression vectors. Proteins and protein complexes which are synthesized *de novo* in the target cell will contain the exogenous gene product, *e.g.*, the modified fusion protein. In order to avoid suppression of the exogenous gene product by the siRNA molecule, the nucleotide sequence encoding the exogenous nucleic acid may be altered at the DNA level (with or without causing mutations on the amino acid level) in the part of the sequence which so is homologous to the siRNA molecule. Alternatively, the endogenous target gene may be complemented by corresponding nucleotide sequences from other species, *e.g.* from mouse.

20

### C. Functional Genomics and/or Proteomics

Preferred applications for the cell or organism of the invention include the analysis of gene expression profiles and/or proteomes. In an especially preferred embodiment an analysis of a variant or mutant form of one or several target proteins is carried out, wherein said variant or mutant forms are reintroduced into the cell or organism by an exogenous target nucleic acid as described above. The combination of knockout of an endogenous gene and rescue by using mutated, *e.g.* partially deleted exogenous target has advantages compared to the use of a knockout cell. Further, this method is particularly suitable for identifying functional domains of the targeted protein.

30 In a further preferred embodiment a comparison, *e.g.* of gene expression profiles and/or proteomes and/or phenotypic characteristics of at least two cells or organisms is carried out. These organisms are selected from: (i) a control cell or control organism without



target gene inhibition, (ii) a cell or organism with target gene inhibition and (iii) a cell or organism with target gene inhibition plus target gene complementation by an exogenous target nucleic acid.

- Furthermore, the RNA knockout complementation method may be used for its preparative purposes, *e.g.* for the affinity purification of proteins or protein complexes from eukaryotic cells, particularly mammalian cells and more particularly human cells. In this embodiment of the invention, the exogenous target nucleic acid preferably codes for a target protein which is fused to an affinity tag. This method is suitable for functional proteome analysis in mammalian cells, particularly human cells.
- Another utility of the present invention could be a method of identifying gene function in an organism comprising the use of shRNA to inhibit the activity of a target gene of previously unknown function. Instead of the time consuming and laborious isolation of mutants by traditional genetic screening, functional genomics would envision determining the function of uncharacterized genes by employing the invention to reduce the amount and/or alter the timing of target gene activity. The invention could be used in determining potential targets for pharmaceuticals, understanding normal and pathological events associated with development, determining signaling pathways responsible for postnatal development/aging, and the like.

- The ease with which RNA can be introduced into an intact cell/organism containing the target gene allows the present invention to be used in high throughput screening (HTS). Solutions containing shRNAs that are capable of inhibiting the different expressed genes can be placed into individual wells positioned on a microtiter plate as an ordered array, and intact cells/organisms in each well can be assayed for any changes or modifications in behavior or development due to inhibition of target gene activity. The amplified RNA can be fed directly to, injected into, the cell/organism containing the target gene. Alternatively, the shRNA can be produced from a vector, as described herein. Vectors can be injected into, the cell/organism containing the target gene. The function of the target gene can be assayed from the effects it has on the cell/organism when gene activity is inhibited. This screening could be amenable to small subjects that can be processed in large number, for example: arabidopsis, bacteria, drosophila, fungi, nematodes, viruses, zebrafish, and tissue culture cells derived from mammals. A nematode or other organism that produces a colorimetric, fluorogenic, or

luminescent signal in response to a regulated promoter (e.g., transfected with a reporter gene construct) can be assayed in an HTS format.

The HTS approach may identify new drug targets. The potential drug targets may also be validated using the present invention. For example, a particular disease phenotype might be induced by a gene mutation or a chemical. RNAi may be used to down-regulate genes and some of these down-regulations might lead to the reversal of the disease phenotype. These genes are potential drug targets. Compounds may be identified to inhibit these genes to treat the disease phenotype.

#### 10 D. Viral delivery vehicles

One challenge that must be met to realize therapeutic applications of RNAi technologies is the development of systems to deliver siRNAs efficiently into mammalian cells. Towards that end, plasmids have been designed expressing short hairpin RNAs, or stem-loop RNA structures, driven by RNA polymerase III (pol III) promoters (T.R. Brummelkamp *et al. Science* (2002) 296:550-553; P.J. Paddison *et al., Genes Dev.* (2002) 16:948-958). The hairpin RNAs are processed to generate siRNAs in cells and thereby induce gene silencing. Pol III promoters are advantageous because their transcripts are not necessarily post-transcriptionally modified, and because they are highly active when introduced in mammalian cells. Polymerase II (pol II) promoters may offer advantages to pol III promoters, including being more easily incorporated into viral expression vectors, such as retroviral and adeno-associated viral vectors, and the existence of inducible and tissue specific pol II dependent promoters. In particular embodiments of the invention, the shRNA sequence is expressed from a Pol III promoter, e.g., U6 promoter. In other embodiments of the invention, the shRNA sequence is under the control of and expressed from a Pol II promoter, e.g., Ubiquitin C promoter.

The limitation of plasmid-based siRNA delivery systems is their dependence on cell transfection methods, which are rarely efficient and limited primarily to established cell lines. Viral based strategies would offer the significant advantage of allowing for efficient delivery to cell lines as well as primary cells.

### E. Methods of treatment

The present invention provides shRNA-expressing constructs that are useful clinically (*e.g.*, in certain prophylactic and/or therapeutic applications). For example, shRNAs can be used, for example, as prophylactic and/or therapeutic agents in the  
5 treatment of diseases or disorders associated with unwanted or aberrant expression of the corresponding target gene.

In one embodiment, the invention provides for prophylactic methods of treating a subject at risk of (or susceptible to) a disease or disorder, for example, a disease or disorder associated with aberrant or unwanted target gene expression or activity.  
10 Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted target gene expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the target gene aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its  
15 progression. Depending on the type of target gene aberrancy, for example, a target gene, target gene agonist or target gene antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein.

In another embodiment, the invention provides for therapeutic methods of treating a subject having a disease or disorder, for example, a disease or disorder  
20 associated with aberrant or unwanted target gene expression or activity. In an exemplary embodiment, the modulatory method of the invention involves contacting a cell capable of expressing target gene with a therapeutic agent that is specific for the target gene or protein (*e.g.*, is specific for the mRNA encoded by said gene or specifying the amino acid sequence of said protein) such that expression or one or more of the  
25 activities of target protein is modulated. These modulatory methods can be performed *in vitro* (*e.g.*, by culturing the cell with the agent) or, alternatively, *in vivo* (*e.g.*, by administering the agent to a subject). As such, the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of a target gene polypeptide or nucleic acid molecule.  
30 Inhibition of target gene activity is desirable in situations in which target gene is abnormally unregulated and/or in which decreased target gene activity is likely to have a beneficial effect.

“Treatment”, or “treating” as used herein, is defined as the application or administration of a prophylactic or therapeutic agent to a patient, or application or administration of a prophylactic or therapeutic agent to an isolated tissue or cell line from a patient, who has a disease or disorder, a symptom of disease or disorder or a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease or disorder, the symptoms of the disease or disorder, or the predisposition toward disease.

Knowledge of shRNAs and their targets would allow specific modulation of shRNA systems to treat any of a number of disorders (including cancer, inflammation, neuronal disorders, *etc.*). Manipulating shRNA regulation of translation of these genes is a novel, powerful, and specific method for treating these disorders.

#### **VIII. Pharmacogenomics and Pharmaceutical Compositions**

With regards to both prophylactic and therapeutic methods of treatment, such treatments may be specifically tailored or modified, based on knowledge obtained from the field of pharmacogenomics. “Pharmacogenomics”, as used herein, refers to the application of genomics technologies such as gene sequencing, statistical genetics, and gene expression analysis to drugs in clinical development and on the market. More specifically, the term refers the study of how a patient's genes determine his or her response to a drug (*e.g.*, a patient's “drug response phenotype”, or “drug response genotype”). Thus, another aspect of the invention provides methods for tailoring an individual's prophylactic or therapeutic treatment with either the target gene molecules of the present invention or target gene modulators according to that individual's drug response genotype. Pharmacogenomics allows a clinician or physician to target prophylactic or therapeutic treatments to patients who will most benefit from the treatment and to avoid treatment of patients who will experience toxic drug-related side effects.

With regards to the above-described agents for prophylactic and/or therapeutic treatments, the agents are routinely incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, antibody, or modulatory compound and a pharmaceutically acceptable carrier. As used herein the language “pharmaceutically acceptable carrier” is

intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, *e.g.*, intravenous, intradermal, subcutaneous, intraperitoneal, intramuscular, oral (*e.g.*, inhalation), transdermal (topical), and transmucosal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity

can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

10 Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those  
15 enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They  
20 can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically  
25 compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant  
30 such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, *e.g.*, a gas such as carbon dioxide, or a nebulizer.

Systemic administration can also be by transmucosal or transdermal means. For  
5 transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active  
10 compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

The compounds can also be prepared in the form of suppositories (*e.g.*, with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.

15 In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.  
20 Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled  
25 in the art, for example, as described in U.S. Patent No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound  
30 calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound

and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit large therapeutic indices are preferred. Although compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the EC50 (*i.e.*, the concentration of the test compound which achieves a half-maximal response) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

When administering shRNAs, it may be advantageous to chemically modify the shRNA in order to increase *in vivo* stability. Preferred modifications stabilize the shRNA against degradation by cellular nucleases.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

This invention is further illustrated by the following examples which should not be construed as limiting. The contents of all references, patents and published patent applications cited throughout this application are incorporated herein by reference.



## EXAMPLES

Mutations in Cu, Zn superoxide dismutase (SOD1) gene cause a subset of amyotrophic lateral sclerosis, a neurodegenerative disease that leads to motor neuron degeneration, paralysis and death (Brown and Robberecht, 2001; Siddique and Lalani, 2002). It has been well established that mutant SOD1 causes motor neuron degeneration by acquisition of a toxic property (Cleveland and Rothstein, 2001). However, neither the molecular basis of this toxic property nor mechanism that leads to motor neuron death is understood. Because of this incomplete understanding of the disease mechanism, rational design of therapy has not produced robust efficacious outcomes. On the other hand, because the toxicity that kills motor neurons originates from the mutated protein (Cleveland and Rothstein, 2001), decrease of the mutant protein should alleviate or even prevent the disease. The following examples demonstrate that RNAi can be used to target mutant SOD1 protein without detrimentally affecting normal SOD1. In particular, the examples teach regulatable silencing of mutant SOD1 in transgenic mice. As described in detail above, the invention features constructs that provide for inducible shRNA expression (and, in turn, gene silencing) when appropriately introduced into cells or animals. These examples teach a shRNA capable of silencing mutant SOD1 as the target gene although the constructs work equally well for the silencing of any target gene, be it a mutant target gene or normal (wild type) target gene.

### **EXAMPLE 1: Generation of Inducible Desilencing Constructs containing a Pol III promoter**

The first type of exemplary construct provided in the instant invention is an inducible desilencing construct that expresses shRNA against mutant SOD1, but upon exposure to Cre recombinase the transgene is excised, thereby inhibiting shRNA expression and its silencing of mutant SOD1 expression.

With respect to this first class of constructs, constructs B-D were generated as follows. Construct B contains two *loxP* sites flanking the entire U6-G93A expression unit (Figure 1B). Therefore, the entire transgene is looped out after Cre recombination.

Construct C, depicted in Figure 1C, contains a *loxP* in the loop region, and another *loxP* in the 3' end of the putative shG93A transcript. Because a minimum of 82-bp between the two *loxP* sites is required for Cre-mediated excision, approximately 200 base pair intervening sequence is inserted in front of the second *loxP* site to increase the length of the sequence between the two *loxP* sites so that this sequence can be excised efficiently. Cre-mediated recombination removes the antisense strand. The resulting construct will be not able to produce shRNA and cannot mediate RNAi, thus causing desilencing. Construct D (also called U6loxG93Alox), depicted in Figure 1D and set forth in SEQ ID NO: 2, has one *loxP* inserted in the U6 promoter region and another *loxP* at the 3' end of the shRNA. Results indicate that this insertion does not affect the function of the U6 promoter. Cre recombination removes a large part of the U6 promoter and the entire shRNA coding sequence, and the looped-out circle cannot produce significant transcription because it lacks an obligatory promoter element DSE (Bark *et al.*, 1987; Carbon *et al.*, 1987; Kunkel and Pederson, 1988). Construct D expresses shG93A has been constructed and verified by sequencing and by *in vitro* Cre-mediated recombination reactions.

## EXAMPLE 2: Generation of Inducible Silencing Constructs containing a Pol III promoter

A second type of construct provided herein is an inducible silencing construct that cannot express shRNA, but upon exposure to Cre recombinase the transgene activates and expresses the shRNA, thereby silencing mutant SOD1 expression. This second class of constructs, which are normally inactive and do not express shRNA, and which, upon exposure to Cre recombinase, result in expression of the shRNA, are called inducible silencing constructs.

An example of this second class of constructs, construct E in Figure 1, is a sequence containing a string of five Ts and a ~200 bp spacer sequence inserted between the sense and antisense strand of the shRNA coding sequence. Flanking this insertion are *loxP* sites on both sides (Figure 1E). The hairpin cannot be expressed because the transcription stops at the five Ts before it reaches the antisense strand. Cre recombinase

removes these five Ts along with the spacer sequence, thereby allowing the synthesis of the entire hairpin.

Another example of this second class of constructs is Construct F (also called U6loxNEOloxG93A), depicted in Figure 1 and the sequence of which is set forth in SEQ ID NO: 3. Construct F contains a U6 promoter that is disrupted by insertion of a non-specific piece of DNA (~1 kb from NEO coding region), which is flanked by *loxP* sites on both sides (Figure 1F) so that it can be excised upon exposure to Cre recombinase. The U6 promoter structure was examined for an insertion site that would interrupt the promoter function, but upon Cre-mediated recombination, the promoter function could recover (*i.e.*, the promoter function is not affected by leaving one *loxP* sequence in it). The U6 promoter is composed of ~250 nucleotides 5' to the U6 snRNA (Paule *et al.*, 2000). It contains 3 essential elements that are indispensable for the promoter function: the distal sequence element (DSE), the proximal sequence element (PSE) and the TATA box (see Figure 1). Early work has found that the number of nucleotides is strictly defined between the TATA box and the transcription initiation site (24 nucleotides), and between the PSE and TATA box (17 nucleotides) (Lescure *et al.*, 1991; Goomer and Kunkel, 1992). Alteration of the distances between these elements seriously impaired the promoter function. Because the length of a single *loxP* is 34 nucleotides, it is longer than the distance between the PSE and TATA, and between TATA and the transcription initiation site. This precludes these two sites for placing the disruption sequence. To avoid interfering with the promoter function after Cre-mediated recombination, a single *loxP* site was inserted into the segment between the DSE and PSE, at ~60 nucleotide from the PSE (Figure 1F). This particular region was chosen because it was not bound to chromatin and therefore, without being bound by theory, it was believed that an insertion of a new sequence would not interfere with nucleosome formation and affect promoter function.

### EXAMPLE 3: Analysis of Inducible Silencing Constructs

SOD1<sup>G93A</sup>GFP expression was quantified in cell lysates by emission scanning using a fluorometer (n = 3) according to the published protocol (Chiu *et al.* 2002) (Figure 2A). Construct A in which only one *loxP* site was placed within the promoter region was tested by cotransfection with the SOD1<sup>G93A</sup>GFP vector and was found to

display a similar a silencing effect as the original U6-G93A construct (Figure 2, compare lanes 4 and 5). These results indicated that insertion of one *loxP* site does not interrupt the normal function of the U6 promoter.

Subsequently, a ~1 kb segment that was PCR-amplified from the Neomycin (NEO) coding region (without the promoter) and that contained *loxP* sequences flanking both sides of the Neo gene was inserted into the construct (named U6loxNEOloxG93A, see Figure 1F). When this construct was tested, the construct did not silence SOD1<sup>G93A</sup>GFP expression in the absence of Cre (Figure 2), indicating shG93A expression was blocked and the U6 promoter function was disrupted. Cre expression led to partial silencing of SOD1<sup>G93A</sup>GFP expression (Figure 2). These results demonstrate that (1) the U6 promoter can tolerate insertion of one *loxP* site between the PSE and DSE, and (2) the U6loxNEOloxG93A shRNA-synthesizing construct functioned as designed.

Figure 2B depicts detection of the transfected SOD1G93AGFP and the endogenous human SOD1 proteins in 293 cells by Western blot. Cells that were cotransfected with U6-blank or U6loxNEOloxG93A demonstrate high SOD<sup>G93A</sup> levels (see lanes 1 and 2 of Figure 2B). In cells cotransfected with U6-G93A, U6loxG93A (a *loxP* site was inserted into the U6 promoter) or U6loxNEOloxG93A and pcDNA-Cre, the SOD<sup>G93A</sup> levels were suppressed (see lanes 3-5 of Figure 2B).

#### EXAMPLE 4: Transgenic Animals

Both constructs (linearized), U6loxG93Alox and U6loxNEOloxG93A, were injected into fertilized mouse eggs at the University of Massachusetts Medical School transgenic core facility to produce transgenic mice. The transgenic mice were identified by PCR using PCR primers that selectively amplify the respective constructs. Mice so identified (founder mice) were then crossed with CMV-Cre mice (obtained from Jackson Laboratory). This line was created using a Cre construct under the control of human cytomegalovirus (CMV) minimal promoter and is well characterized (Schwenk *et al.*, 1995). The transgene was incorporated into the X chromosome. Nevertheless, when this transgenic line was crossed with a *loxPstoploxP*-LacZ reporter transgenic line, all cells in the female doubly transgenic progenies expressed lacZ. This indicates that the

stop sequence was successfully excised in all cells. This is apparently due to the early expression of Cre during embryonic development before the onset X-chromosome inactivation at the implantation stage (Schwenk *et al.*, 1995). A possible alternative to this line is  $\beta$ -actin-Cre mice, which express Cre ubiquitously (Lewandoski *et al.*, 1997).

- 5 This alternative line is also available from Jackson Laboratory. After the crossing, various tissues from both doubly and singly transgenic mice are characterized, e.g., by determining tissue expression pattern of shRNA by Northern blot analysis, and for completeness of the transgene recombination by Southern blot analysis.

- Lines that express high levels of shG93A in all tissues and execute Cre  
10 recombination in all tissues can further be crossed with SOD1<sup>G93A</sup> mice to make triply transgenic mice. The SOD1 expression pattern is examined using Western blots of various tissues, and semi-quantitative *in situ* hybridization and immunofluorescence on tissue sections. The extent of disease phenotype inhibition is also examined.

15 **EXAMPLE 5: Tetracycline Regulatable Silencing Constructs containing POL II promoters**

- Ubiquitin C promoter (UbCP) is a Pol II promoter that is active ubiquitously and constitutively in all mammalian cells (Lois, 2002). Previous work has mapped this promoter and it has been used widely in culture and in animals to express genes (Li,  
20 2003). As provided in this Example, the Ubiquitin C promoter has been modified so that it can be regulated temporally and spatially in culture and in animals. The basic promoter elements include a 335 bp 5' promoter region, exon 1 and the first intron. Exon 1 is a non-coding exon but may contain some regulatory elements for ubiquitin C expression. The basic construct consists of the above promoter elements, cDNA coding  
25 for the EGFP protein (Invitrogen) and the SV40 poly A element (*UbCP-EGFP* in Figure 3, SEQ ID NO: 4).

- To create an expression vector that can be regulated by tetracycline, two constructs were designed. In the first construct, two tetracycline responsive elements (TREs) were placed in the UbCP (Figure 3, *UbCP-TRE1-EGFP*; SEQ ID NO: 5). In the  
30 second construct, the two TREs were placed in the first exon (Figure 3, *UbCP-TRE2-EGFP*; SEQ ID NO: 6). Both constructs expressed EGFP, although construct 2 (*UbCP-*

*TRE2-EGFP*) provided better expression than construct 1, (*UbCP-TRE1-EGFP*).  
*UbCP-TRE2-EGFP* expressed at the same level as unmodified *UbCP-EGFP*, while  
*UbCP-TRE1-EGFP* expressed at lower levels (Figure 4). Thus, *UbCP-TRE2-EGFP*  
offers advantages over *UbCP-TRE1-EGFP*. As expected, the expression of EGFP could  
5 be suppressed in the presence of tTS, a repressor that binds to TREs (Figure 4).

Next, to use this expression vector system to express shRNAs, the vector *UbC-  
TRE2-mirMSOD2-tTS-IRES-EGFP* (Figure 3, SEQ ID NO: 7) was created. This is a  
self repressing construct, wherein UbCP directs synthesis of an mRNA that contains  
exon1, intron 1 containing a sequence for mirMSOD2 expression (see below), tTS  
10 coding sequence, IRES (internal ribosomal entry site) and EGFP coding sequence. The  
mirMSOD1 sequence directs expression of a shRNA targeting mouse SOD2 gene,  
although this can be a sequence coding for a short hairpin RNA targeting any other gene  
(see further description below). In the absence of the inducer doxycyclin (a tetracycline  
analogue), the UbCP directs synthesis of tTS and EGFP. However, this expression is  
15 suppressed by tTS because it binds to TRE and blocks the promoter. Upon addition of  
the inducer doxycyclin, which binds to tTS and prevents it from binding to the TRE, the  
suppression of transcription is released and transcription increases. The construct was  
tested by transfecting *UbC-TRE2-mirMSOD2-tTS-IRES-EGFP* into HEK293 cells. In  
two separate experiments, when vector was transfected in the absence of doxycyclin, the  
20 basal level of expression of EGFP was suppressed at low levels. Upon addition of  
doxycyclin, expression of EGFP was increased (Figure 5).

In a different design, the tTS can alternatively be provided by an independent Pol  
II promoter. In that case, the background expression of the mirMSOD2 and EGFP are  
expected to be lower than what has been observed in *UbC-TRE2-mirMSOD2-tTS-  
25 IRES-EGFP*, as shown in Figure 5.

#### **EXAMPLE 6: Cre/Lox Regulatable Silencing Constructs containing Pol II promoters**

Vectors were next designed to allow shRNA expression from a Pol II promoter  
30 to be controlled in specific cells. The vector *UbCP-lox-RFP-lox-mirMSOD2-EGFP*  
(Figure 3; SEQ ID NO: 8) was created. In this construct, UbCP normally transcribes  
RFP mRNA, which terminates at the poly site. However, because the RPF gene is

flanked by two loxP sites, upon exposure to cre, the RFP gene is excised and the construct is converted to *UbCP-lox-mirMSOD2-EGFP*. The resulting recombined sequence transcribes a message that contains an intron with an shRNA against the mouse SOD2 gene (or any other genes) and an EGFP gene.

5       A second, complementary vector *UbCP-lox-mirMSOD2-EGFP-lox-RFP* (Figure 3; SEQ ID NO: 9) was also created. In this vector, the UbCP normally directs synthesis of the hairpin and EGFP. However, upon exposure to cre, the hairpin and EGFP are excised, thus preventing hairpin expression, while the RFP gene is under control of the UbCP, thus activating RFP expression.

10       To test these constructs, both *UbCP-lox-RFP-lox-mirMSOD2-EGFP* and *UbCP-lox-mirMSOD2-EGFP-lox-RFP* were cotransfected with either pcDNA3 empty vector or pcDNA3-cre. When *UbCP-lox-RFP-lox-mirMSOD2-EGFP* was cotransfected with pcDNA3 empty vector, RFP expression was observed by microscopic analysis. When this same vector was cotransfected with pcDNA3-cre, GFP was expressed. The  
15       converse was true for the *UbCP-lox-mirMSOD2-EGFP-lox-RFP* construct. When *UbCP-lox-mirMSOD2-EGFP-lox-RFP* was cotransfected with pcDNA3 empty vector, GFP was expressed. When this same construct was cotransfected with pcDNA3-cre, RFP was expressed. These data demonstrated that these constructs function according to their design.

20       The mirMSOD2 is an shRNA that incorporates a miRNA hairpin structure (Figure 6; SEQ ID NO: 1). MirMSOD2 is placed in intron 1 and is intended to silence mouse SOD2 (see Figure 3). When intron 1 is spliced out, mirMSOD2 will be processed by Drosha to produce an shRNA, which in turn will be exported out of the nucleus by exportin 5. The shRNA will be further processed by Dicer in the cytoplasm,  
25       form a complex with RISC and mediate RNAi against the SOD2 mRNA. Thus, SOD2 expression should be inhibited when the intron 1 is expressed. The DNA sequence corresponding to mirMSOD2 is provided in SEQ ID NO: 1. It will be understood that a mirMSOD2 shRNA sequence is the corresponding RNA sequence in which the thymidines are replaced by uridines.

30       To test whether SOD2 expression was inhibited when intron 1 was expressed, mouse NF-1 cells were transfected with *UbCP-TRE2-mirMSOD2-tTS-IRES-EGFP*. Doxycyclin induced dramatic inhibition of expression of the endogenous SOD2 gene

(Figure 7, compare lane 2 with lane 4). Likewise, when *UbCP-lox-RFP-lox-mirMSOD2-EGF* was cotransfected with pcDNA3-cre, dramatic inhibition of SOD2 expression was observed (Figure 7, compare lane 3 with lane 5). These results indicated that the mirMSOD2 hairpin vectors function as designed.

5

### Discussion of Examples 5 and 6

The regulatable shRNA expression system utilizing a Pol II promoter, as described in Examples 5 and 6, should function *in vivo* because (1) Pol II is the promoter used endogenously to synthesize miRNA, and (2) the endogenous miRNA structure has  
10 been applied in designing the shRNA. In addition, because a wide range of Pol II promoters with different temporal and spatial control in animals have already been characterized, the system provided herein can be used for inducing silencing at specific developmental stages or in specific cell types. Furthermore, the constructs of the instant invention solve the common problem when using RNAi *in vivo* of determining in which  
15 cell types the shRNA is expressed. Because the constructs provided herein containing a Pol II promoter direct expression of shRNA and marker proteins (*e.g.*, GFP or RFP) at the same time, such marker protein expression marks the cells in which the shRNAs are expressed.

20 The following references are incorporated herein by reference:

Chen Y, Stamatoyannopoulos G, Song C-Z (2003) Down-Regulation of CXCR4 by Inducible Small Interfering RNA Inhibits Breast Cancer Cell Invasion in Vitro. *Cancer Res* 63:4801-4804.

25 Coumoul X, Li W, Wang R-H, Deng C (2004) Inducible suppression of Fgfr2 and Survivin in ES cells using a combination of the RNA interference (RNAi) and the Cre-LoxP system. *Nucl Acids Res* 32:e85-.

Gupta S, Schoer RA, Egan JE, Hannon GJ, Mittal V (2004) From the Cover: Inducible, reversible, and stable RNA interference in mammalian cells. *PNAS* 101:1927-  
30 1932.

Kasim V, Miyagishi M, Taira K (2004) Control of siRNA expression using the Cre-loxP recombination system. *Nucl Acids Res* 32:e66-.



- Li X, Makela S, Streng T, Santti R, Poutanen M (2003) Phenotype characteristics of transgenic male mice expressing human aromatase under ubiquitin C promoter. *The Journal of Steroid Biochemistry and Molecular Biology* 86:469-476.
- Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D (2002) Germline transmission and  
5 tissue-specific expression of transgenes delivered by lentiviral vectors. *Science* 295:868-872.
- Matsukura S, Jones PA, Takai D (2003) Establishment of conditional vectors for hairpin siRNA knockdowns. *Nucl Acids Res* 31:e77-.
- Tiscornia G, Tergaonkar V, Galimi F, Verma IM (2004) From The Cover: CRE  
10 recombinase-inducible RNA interference mediated by lentiviral vectors. *PNAS* 101:7347-7351.
- van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D, Holstege FC, Brummelkamp TR, Agami R, Clevers H (2003) Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA  
15 vector. *EMBO Rep* 4:609-615.
- Zeng Y, Cullen BR (2003) Sequence requirements for micro RNA processing and function in human cells. *Rna* 9:112-123.

20 It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

**What is Claimed:**

1. A construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the construct further comprising a first loxP site upstream of the promoter and a second loxP site downstream of the shRNA encoding sequence, the loxP sites being in the same orientation such that the promoter and encoding sequences are excisable upon exposure to Cre.
2. A construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the shRNA encoding sequence comprising a first stem-encoding portion, a loop-encoding portion, and a second stem-encoding portion, wherein the construct further comprises spacer DNA downstream of the shRNA encoding sequence, a second loxP site downstream of the spacer DNA, and a first loxP site within the loop-encoding portion of the shRNA encoding sequence, the loxP sites being in the same orientation such that the spacer DNA and second stem-encoding sequence are excisable upon exposure to Cre.
3. A construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the U6 promoter comprising (a) a distal sequence element (DSE); (b) a proximal sequence element (PSE); and (b) a TATA box, operably linked, wherein the construct further comprises a first loxP site downstream of the shRNA encoding sequence, and a second loxP site between the DSE and the PSE, the loxP sites being in the same orientation such that the shRNA encoding sequences and a portion of the promoter comprising the PSE and the TATA box are excisable upon exposure to Cre.
4. A construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the shRNA encoding sequence comprising a first stem-encoding portion, a loop-encoding portion, and a second stem-encoding portion, the loop-encoding portion comprising a first loxP site operably linked to a transcription termination signal upstream of a spacer DNA and a second loxP site, the loxP sites being in the same orientation such that the first loxP site, termination signal and spacer DNA are excisable upon exposure to Cre.

5. A construct comprising a U6 promoter operably linked to a shRNA encoding nucleic acid sequence, the U6 promoter comprising (a) a distal sequence element (DSE); (b) a proximal sequence element (PSE); and (b) a TATA box, operably linked, wherein the construct further comprises a first loxP site and a second loxP site, said sites being interrupted by spacer DNA, between the DSE and the PSE, the loxP sites being in the same orientation such that a loxP site and the spacer DNA are excisable upon exposure to Cre.
6. An inducible desilencing construct for the expression of a shRNA, the construct comprising a promoter element operably linked to a shRNA encoding element and further comprising a first and second recombinase-sensitive element in an appropriate orientation such that all or a portion of the promoter or shRNA encoding element is excisable upon exposure to Cre:
7. The construct of claim 6, wherein the first recombinase-sensitive element is upstream of the promoter and the second recombinase-sensitive element is downstream of the shRNA encoding element.
8. The construct of claim 6, wherein the first recombinase-sensitive element is within the shRNA encoding element and the second recombinase-sensitive element is downstream of the shRNA encoding element.
9. The construct of claim 8, wherein the first element is within a loop portion of the shRNA encoding element.
10. The construct of claim 8, wherein the construct further includes a spacer nucleotide sequence between the shRNA encoding element and the second recombinase-sensitive element.
11. The construct of claim 10, wherein the spacer is between 50 and 200 nucleotides in length.

12. The construct of claim 6, wherein the first recombinase-sensitive element is within the promoter and the second recombinase-sensitive element is downstream of the shRNA encoding element.
- 5 13. The construct of claim 12, wherein the first recombinase-sensitive element is downstream of at least one obligatory element in said promoter.
14. The construct of claim 12, wherein the first recombinase element is downstream of a DSE element.
- 10 15. An inducible silencing construct for the expression of a shRNA, the construct comprising a promoter element operably linked to a shRNA encoding element, the promoter or shRNA encoding element being interrupted by DNA sequences flanked by a first and second recombinase-sensitive element in an appropriate orientation such that all  
15 or a portion of the DNA sequences is excisable upon exposure to Cre.
16. The construct of claim 15, wherein the DNA sequences flanked by a first and second recombinase-sensitive element are within the promoter.
- 20 17. The construct of claim 16, wherein the promoter is a Pol III promoter.
18. The construct of claim 17, wherein the promoter is U6 comprising a distal sequence element (DSE), proximal sequence element (PSE) and TATA box.
- 25 19. The construct of claim 18, wherein the DNA sequences flanked by a first and second recombinase-sensitive element are between the DSE and PSE.
20. The construct of claim 15, wherein the DNA sequences flanked by a first and second recombinase-sensitive element are within the shRNA encoding element.
- 30 21. The construct of claim 20, wherein the DNA sequences flanked by a first and second recombinase-sensitive element comprise a transcription termination signal.

22. The construct of any one of claims 16-21, wherein the construct further includes a spacer nucleotide sequence between the first recombinase-sensitive element and the second recombinase-sensitive element.
- 5 23. The construct of claim 22, wherein the spacer is between about 50 and 200 nucleotides in length.
24. An inducible silencing construct for the expression of a shRNA, the construct  
10 comprising a ubiquitin C promoter (Ubc) operably linked to an intron comprising an shRNA encoding element, the Ubc promoter comprising a 5' promoter region and exon 1, operably linked, wherein the construct further comprises one or more tetracycline responsive elements (TRE) within the 5' promoter region or exon 1.
- 15 25. The construct of claim 24, further comprising a tetracycline transcriptional repressor (tTs) encoding nucleic acid sequence and an internal ribosomal entry site (IRES).
26. The construct of claim 24 or 25, further comprising a marker protein encoding  
20 nucleic acid sequence.
27. An inducible silencing construct for the expression of a shRNA, the construct comprising a ubiquitin C promoter (UbcP) operably linked to an intron, the Ubc promoter comprising a 5' promoter region and exon 1, operably linked, wherein the  
25 intron comprises an shRNA encoding element downstream of a transcription termination signal, and wherein the construct further comprises a first loxP site in said exon 1, and a second loxP site between the transcription termination signal and the shRNA encoding element, the loxP sites being in the same orientation such that a portion of the intron comprising the transcription termination signal is excisable upon exposure to Cre.
- 30 28. The construct of claim 27 further comprising a marker protein encoding nucleic acid sequence upstream of the transcription termination site.

29. The construct of claims 27 or 28, further comprising a marker protein nucleic acid sequence downstream of the shRNA encoding element.
- 5 30. An inducible desilencing construct for the expression of a shRNA, the construct comprising a ubiquitin C promoter (UbCP) operably linked to an intron, the Ubc promoter comprising a 5' promoter region and exon 1, operably linked, wherein the intron comprises an shRNA encoding element upstream of a transcription termination signal, and wherein the construct further comprises a first loxP site in said exon 1, and a  
10 second loxP site downstream of the transcription termination signal, the loxP sites being in the same orientation such that a portion of the intron comprising the shRNA encoding element and the transcription termination signal is excisable upon exposure to Cre.
31. The construct of claim 30, further comprising a marker protein encoding nucleic  
15 acid sequence between the shRNA encoding element and the transcription termination signal.
32. The construct of claims 30 or 31, further comprising a marker protein encoding nucleic acid sequence downstream of the second loxP site.  
20
33. The construct of any one of claims 26, 28, 29, 31 and 32, wherein the marker protein is red or green fluorescent protein.
34. The construct of any one of claims 6-33, wherein the recombination-sensitive  
25 element is a loxP site.
35. The construct of any one of claims 1-34, wherein the shRNA comprises a sequence sufficiently complementary to a target mRNA to mediate degradation of said target.  
30
36. The construct of claim 35, wherein said target mRNA encodes a mutant protein.

37. The construct of claim 36, wherein said mutant protein is a disease-causing mutant.
38. The construct of claim 37, wherein the mutant protein is SOD1.
- 5 39. The construct of claim 38, wherein said mutant protein is SOD1<sup>G93A</sup>.
40. The construct of claim 38, wherein said mutant protein is SOD1<sup>G85R</sup>.
- 10 41. The construct of any one of the preceding claims for the treatment of a disease.
42. The construct of claim 41, wherein said disease is caused by aberrant gene function.
- 15 43. The construct of claim 41, wherein said disease is a dominant, gain-of-function mutation.
44. The construct of claim 42, wherein said disease is a neurological disease.
- 20 45. A vector comprising the construct of any one of the preceding claims.
46. The vector of claim 45, wherein said vector is a viral vector.
47. The vector of claim 46, wherein said vector is an AAV or lentivirus.
- 25 48. A cell comprising a construct of any one of claims 1-44.
49. A cell comprising the vector of any one of claims 46-47.
- 30 50. The cell comprising the construct of any one of claims 1-44 and 46-47, wherein the cell is an animal cell.

51. A nonhuman transgenic animal carrying a transgene comprising the constructs of any one of claims 1-44.
52. A nonhuman homologous recombinant animal which contains cells from any one  
5 of claims 48-49.
53. A method for promoting inducible RNAi, the method comprising introducing into a cell the construct of any one of claims 1-44 under conditions such that shRNA expression is inducible.
- 10 54. The method of claim 53, wherein the cell is present in a subject.
55. The method of claim 53, wherein the cell is a cultured cell.
- 15 56. The method of claim 53, wherein said introducing comprises transfecting said cell.
57. The method of claim 53, wherein said introducing comprises infecting said cell with a viral vector.
- 20 58. A method of promoting inducible RNAi in a subject, the method comprising administering the construct of any one of claims 1-44.
59. A method for selectively inhibiting mutant gene expression *in vivo* or *in vitro*,  
25 the method comprising introducing into a host cell the construct of any one of claims 1-44 under conditions such that said shRNA is expressed, thereby inhibiting mutant gene expression.
60. The method of claim 59, wherein the shRNA does not inhibit expression of the  
30 wild type allele.



61. A method for treating a disease in a subject, the method comprising administering the construct of any one of claims 1-44, thereby treating a disease in a subject.

5 62. The method of claim 61, wherein the disease is caused by aberrant gene function.

63. The method of claim 61, wherein the disease is caused by a mutation that is a dominant, gain-of-function mutation.

10 64. A method for identifying a compound which modulates RNAi, the method comprising:

(a) contacting a cell comprising the construct of any one of claims 1-44 with a test compound; and

15 (b) determining the effect of the test compound on an indicator of RNAi activity in said cell, thereby identifying a compound which modulates RNAi.

65. A compound identified according to the method of claim 64.

20 66. A method for modulating RNAi, the method comprising contacting a cell expressing the construct of any one of claims 1-44 with the compound of claim 65 in a sufficient concentration to modulate the activity of RNAi.

25 67. A method for modulating RNAi, the method comprising contacting a cell expressing the construct of any one of claims 48-49 with a compound which binds to said construct in a sufficient concentration to modulate the activity of RNAi.

68. A method for deriving information about the function of a gene in a cell or organism comprising:

30 (a) introducing into said cell or organism the construct of any one of claims 1-44;

(b) maintaining the cell or organism under conditions such that RNAi can occur;

(c) determining a characteristic or property of said cell or organism; and

(d) comparing said characteristic or property to a suitable control,  
the comparison yielding information about the function of the gene.

69. A method of validating a candidate protein as a suitable target for drug discovery  
5 comprising:

- (a) introducing into a cell or organism the construct of any one of claims 1-44;
- (b) maintaining the cell or organism under conditions such that RNAi can occur;
- (c) determining a characteristic or property of said cell or organism; and
- (d) comparing said characteristic or property to a suitable control,

10 the comparison yielding information about whether the candidate protein is a  
suitable target for drug discovery.

70. A kit comprising reagents for activating RNAi in a cell or organism, said kit  
comprising:

- 15
- (a) the construct of any one of claims 1-44; and
  - (b) instructions for use.

71. A method of excising a DNA sequence, the method comprising:

- 20
- (a) exposing the construct of any one of claims 1-23 and 27-33 to Cre  
recombinase;
  - (b) allowing recombination; thereby excising a portion of said DNA sequence.

72. A method of promoting target gene expression, the method comprising:

- 25
- (a) exposing the construct of any one of claims 1-3, 6-14 and 30-32 to a Cre  
recombinase;
  - (b) excising of a portion of the shRNA flanked by loxP sites; and
  - (c) disrupting expression of the shRNA, thereby allowing the target gene to be  
expressed.

30 73. The method of claim 72, wherein said disrupted expression results in the  
silencing of a mutant gene.

74. The method of claim 73, wherein the mutant gene is SOD1.

75. A method of recovering promoter function, the method comprising exposing the  
5 construct of any one of claims 5 and 15-19 to a Cre recombinase protein under  
conditions such that shRNA expression is activated, thereby recovering said promoter  
function.







76. A method of disrupting promoter function, the method comprising  
10 (a) exposing the construct of any one of claims 1, 3 and 12-14 to a Cre  
recombinase;  
(b) allowing recombination, thereby disrupting promoter function.


77. A method of inhibiting expression of a target gene, the method comprising:  
15 (a) exposing the construct of any one of claims 5 and 15-19 to a Cre recombinase;  
(b) activating said promoter; and  
(c) expressing said shRNA, thereby inhibiting target gene expression.

78. The method of claim 76 or 77, wherein said promoter may be regulated in an  
20 animal.


79. The method of claim 78, wherein said promoter is regulated temporally.

80. The method of claim 78, wherein said promoter is regulated spatially.


*Fig. 1A**Fig. 1B**Fig. 1C**Fig. 1D**Fig. 1E**Fig. 1F*




*Fig. 2A*




*Fig. 2B*


*Fig. 3*

*Fig. 4*

## Testing self-inducible UbCTRE driven-mSOD2 shRNA expression


*Fig. 5*





mirMSOD2 structure

*Fig. 6*



1. Untransfected cell lysate
2. UbC-TRE2-mirMSOD2-tTS-IRES-EGFP
3. UbC-lox-RFP-lox-mirMSOD2-EGFP+pcDNA3
4. UbC-TRE2-mirMSOD2-tTS-IRES-EGFP + Doxycyclin
5. UbC-lox-RFP-lox-mirMSOD2-EGFP+pcDNA3-cre

*Fig. 7*

## SEQUENCE LISTING

<110> University of Massachusetts, et al.

<120> REGULATABLE PROMOTERS FOR SYNTHESIS OF SMALL HAIRPIN RNA

<130> UMY-072PC

<150> 60/488,510

<151> 2003-07-18

<160> 9

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 106

<212> DNA

<213> Artificial Sequence

<220>

<223> synthetic shRNA

<400> 1

```
tgctgttgac agtgagcgac caagggagat tcgttgcaac tcagtgaagc cacagatgtg 60
agttgtaaca tctcccttgg ctgcctactg cctcggactt caaggg 106
```

<210> 2

<211> 3369

<212> DNA

<213> Artificial Sequence

<220>

<223> expression construct

<400> 2

```
ctaaattgta agcgttaata ttttggtaaa attcgcgtta aatttttgtt aaatcagctc 60
attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga 120
gataggggtg agtggtgttc cagtttgga caagagtcca ctattaaaga acgtggactc 180
caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc 240
ctaatacaagt tttttggggt cgaggtgccg taaagcacta aatcgggaacc ctaaaggagag 300
cccccgattt agagcttgac ggggaaaagcc ggcgaacgtg gcgagaaagg aagggaagaa 360
agcgaaaagga gcgggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac 420
cacacccgcc gcgttaatg cggcgctaca gggcgctgc cattcgccat tcaggctgcg 480
caactgttgg gaaggcgat cgggtgcggc ctcttcgcta ttacgccagc tggcgaaagg 540
gggatgtgct gcaaggcgat taagtgggt aacgccaggg ttttcccagt caccagcttg 600
taaaacgacg gccagtgaat tgtaatacga ctactatag ggcgaattgg gtaccgctag 660
caatctcgag ccttggttag aactagtggg tccgacgccg ccactcttag gcccgcgccg 720
gccccctcgc acagacttgt gggagaagct cggctactcc cctgccccgg ttaatttgca 780
tataatatatt cctagtaact atagaggctt aatgtgcgat aaaagacaga taatcagatc 840
tataacttcg tatagcatac attatacga gttatagatc tctgttcttt ttaatactag 900
ctacatttta catgataggc ttggatttct ataagagata caaatactaa attattattt 960
taaaaaacag caaaaagga aactcaccct aactgtaaag taattgtgtg ttttgagact 1020
ataaatatcc cttggagaaa agccttggtt gacaaagatg ctgtggccga taagcttatc 1080
ggccacagca tctttgtctt tttgaattca ataacttcgt atagcatata ttatagcaag 1140
ttatgcggcc gccaccgagg tggagctcca gcttttggtc cctttagtga gggttaattt 1200
cgagcttggc gtaatcatgg tcatagctgt ttctgtgtg aaattgttat ccgctcaca 1260
ttccacacaa catacgagcc ggaagcataa agtgtaaagc ctgggggtgcc taatgagtga 1320
gctaactcac attaatgctg ttgcgctcac tgcccgttt ccagtcggga aacctgtcgt 1380
```

```

gccagctgca ttaatgaatc ggccaacgcg cggggagagg cggtttgctt attgggcgct 1440
cttcgcgttc ctcgctcact gactcgctgc gctcggctcg tcggctgcgg cgagcggtat 1500
cagctcactc aaaggcggtc atacggttat ccacagaatc aggggataac gcaggaaaga 1560
acatgtgagc aaaaggccag caaaaggcca ggaaccgtaa aaaggccgcg ttgctggcgt 1620
ttttccatag gctccgcccc cctgacgagc atcacaaaaa tcgacgctca agtcagaggc 1680
ggcgaaaccc gacaggacta taaagatacc aggcgtttcc ccctggaagc tccctcgctg 1740
gctctcctgt tccgaccctg ccgcttaccg gatacctgtc cgcctttctc ccttcgggaa 1800
gcgtggcgct ttctcatagc tcacgctgta ggatatctag ttcgggtgtag gtcgttcgct 1860
ccaagctggg ctgtgtgcac gaaccccccg ttcagcccca ccgctgcgcc ttatccggta 1920
actatcgtct tgagtccaac ccggtaaagc acgacttacc gccactggca gcagccactg 1980
gtaacaggat tagcagagcg aggtatgtag cgggtgctac agagtctctg aagtgggtgc 2040
ctaactacgg ctacactaga aggacagtat ttggtatctg cgctctgctg aagccagtta 2100
ccttcggaaa aagagtttgt agctcttgat ccggcaaaaa aaccaccgct ggtagcgggt 2160
gtttttttgt ttgcaagcag cagattacgc gcagaaaaaa aggatctcaa gaagatcctt 2220
tgatcttttc tacggggtct gacgctcagt ggaacgaaaa ctcacgttaa gggattttgg 2280
tcatgagatt atcaaaaagg atcttcacct agatcctttt aaattaaata tgaagtttta 2340
aatcaatcta aagtatatat gagtaaaact ggtctgacag ttaccaatgc ttaatcagtg 2400
aggcacctat ctcagcgatc tgtctatttc gttcatccat agttgcctga ctccccgtcg 2460
tgtagataac tacgatacgg gagggcttac catctggccc cagtgcctga atgataccgc 2520
gagacccacg ctaccggct ccagatttat cagcaataaa ccagccagcc ggaagggccg 2580
agcgcagaag tggctcctga actttatccg cctccatcca gtctattaat tgttgccggg 2640
aagctagagt aagtagttcg ccagttaata gtttgcgcaa cgttgttgcc attgctacag 2700
gcacgttgtt gtcacgctcg tcgtttggta tggttcatt cagctccggg tcccaacgat 2760
caaggcgagt tacatgatcc ccatgttgtt gcaaaaaagc ggtagctcc ttcggctcct 2820
cgatcgttgt cagaagtaag ttggccgcag tgttatcact catggttatg gcagcactgc 2880
ataattctct tactgtcatg ccacccgtaa gatgcttttc tgtgactggg gagtactcaa 2940
ccaagtcatt ctgagaatag tgtatgcggc gaccgagttg ctcttgcccg gcgtcaatac 3000
gggataatac cgcgccacat agcagaactt taaaagtgct catcattgga aaacgttctt 3060
cggggcgaaa actctcaagg atcttaccgc tgttgagatc cagttcgatg taacccactc 3120
gtgcacccaa ctgatcttca gcacctttta ctttcaccag cgtttctggg tgagcaaaaa 3180
caggaaggca aaatgccga aaaaaggga taaggcgac acggaaatgt tgaatactca 3240
tactcttcct ttttcaatat tattgaagca ttatcaggg ttattgtctc atgagcggat 3300
acatatattga atgtatttag aaaaataaac aaataggggt tccgcgcaca tttccccgaa 3360
aagtgcac
3369

```

&lt;210&gt; 3

&lt;211&gt; 4388

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; expression construct

&lt;400&gt; 3

```

ctaaattgta agcgttaata ttttggtaaa attcgcgtta aatttttggt aaatcagctc 60
attttttaac caataggccg aaatcggcaa aatcccttat aaatcaaaag aatagaccga 120
gatagggttg agtgtgttcc cagtttgga caagagtcca ctattaaaga acgtggactc 180
caacgtcaaa gggcgaaaaa ccgtctatca gggcgatggc ccactacgtg aaccatcacc 240
ctaatacagt ttttggggt cgaggtgccg taaagcacta aatcggaaac ctaaaggag 300
ccccgattt agagcttgac ggggaaagcc ggcgaaactg gcgagaaagg aagggaagaa 360
agcgaaagga gcggcgcta gggcgctggc aagtgtagcg gtcacgctgc gcgtaaccac 420
cacaccgcc gcgttaatg cgcgctaca gggcgctcc cattcgccat tcaggctgcg 480
caactgttgga gaaggcgat cgggtgcggc ctcttcgcta ttacgccagc tggcgaaagg 540
gggatgtgct gcaaggcgat taagtgggt aacgccaggg ttttccagc cagcagcttg 600
taaaacgacg gccagtgaat tgtaatacga ctactatag ggcgaaattg gtaccgctag 660
caatctcgag ccttggttag aactagtggg tccgacgccg ccactcttag gccgcgcgcg 720
gccocctcgc acagacttgt gggagaagct cggtactcc cctgccccgg ttaatttgca 780
tataatattt ctagttaact atagaggctt aagtgtcgat aaaagacaga taatcagatc 840
taataacttc gtatagcata cattatacga agttatatta agggttccgg atctcgaggc 900
ttgattcttc tgacacaaca gtctcgaact taaggctaga gccaccatga ttgaacaaga 960
tggattgcac gcaggttctc cggccgcttg ggtggagagg ctattcggct atgactgggc 1020

```

```

acaacagaca atcggtgct ctgatgccgc cgtgttcggg ctgtcagcgc aggggcgccc 1080
ggttcttttt gtcaagaccg acctgtccgg tgccctgaat gaactgcagg acgaggcagc 1140
gcggctatcg tggttgcca cgacgggcbt tccttgccga gctgtgctcg acgttgtcac 1200
tgaagcggga agggactggc tgctattggg cgaagtgcgg gggcaggatc tcctgtcac 1260
tcaccttgct cctgccgaga aagtatccat catggctgat gcaatgcggc ggctgcatac 1320
gcttgatccg gctacctgcc cattcgacca ccaagcgaaa catcgcatcg agcgagcacg 1380
tactcggatg gaagccggtc ttgtcgatca ggatgatctg gacgaagagc atcaggggct 1440
cgcgccagcc gaactgttcg ccaggtcaa ggccgcgatg cccgacggcg aggatctcgt 1500
cgtgacccat ggcatgcct gcttgccgaa tatcatgggt gaaaatggcc gctttctctg 1560
attcatcgac tggggcggc tgggtgtggc ggaccgctat caggacatag cgttggtctac 1620
ccgtgatatt cgtgaagagc ttggcggcga atgggtgac cgcttcctcg tgctttacgg 1680
tatcgccgct cccgattcgc agcgcatcgc ctctatcgc ctcttgacg agttctctcg 1740
agcgggactc tgggggttcga aatgaccgac caagcgacgc ccaacctgcc atcacgatgg 1800
ccgcaataaa atatctttat ttctattaca tctgtgtgtt gggtttttgt gtgaatcgat 1860
agcgataagg atgctagcag gtcgagggac ctaataactt cgtatagcat acattatacg 1920
aagttataga tctctgttct ttttaataact agctacattt tacatgatag gcttggtatt 1980
ctataagaga tacaataact aaattattat tttaaaaaac agcacaanaag gaaactcacc 2040
ctaactgtaa agtaattgtg tgttttgaga ctataaatat cccttggaag aaagccttgt 2100
ttgacaaaga tgctgtggcc gataagctta tcggccacag catctttgtc tttttgaatt 2160
catgcggccg ccaccgcbgt ggagctccag cttttgttcc ctttagtgag gggttaatttc 2220
gagcttgccg taatcatggt catagctgtt tcctgtgtga aattgtttatc cgctcacaa 2280
tccacacaac atacgagccg gaagcataaa gtgtaaagcc tgggggtgcct aatgagtgag 2340
ctaactcaca ttaattgcgt tgcgctcact gcccgcttcc cagtcgggaa acctgtcgtg 2400
ccagctgcat taatgaatcg gccaacgcgc ggggagaggc gggttgcgta ttgggcgctc 2460
ttccgcttcc tgctcactg actcgtcgc ctgggtcgtt cgggtgcggc gagcgggtatc 2520
agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg caggaaagaa 2580
catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcbt tgctggcgtt 2640
tttccatagg ctccgcccc ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg 2700
gcgaaaccgg acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg 2760
ctctcctggt ccgacctgc cgtttaccgg atacctgtcc gcctttctcc ctccgggaag 2820
cgtggcgctt tctcatagct cagctgttag gtatctcagt tcgggttagg tcgttcgctc 2880
caagctgggc tgtgtgcacg aacccccgt tcagcccgac cgctgcgcct tatccggtaa 2940
ctatcgtctt gagtccaacc cggtaagaca cgacttatcg ccactggcag cagcactgg 3000
taacaggatt agcagagcga ggtatgtagg cgggtgtaca gagttcttga agtggtggcc 3060
taactacggc tacactagaa ggacagtatt tggatctgct gctctgctga agccagttac 3120
cttcggaaaa agagttggtg gctcttgatc cggcaaaaca accaccgctg gtagcgggtg 3180
tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatccttt 3240
gatcttttct acgggtctg acgctcagtg gaacgaaac tcacgttaag ggatttttgt 3300
catgagatta tcaaaaagga tcttcaccta gatcctttta aattaaaaat gaagttttta 3360
atcaatctaa agtatatatg agtaaaactg gtctgacagt taccaatgct taatcagtga 3420
ggcacctatc tcagcgatct gtctatttct ttcattcata gttgcctgac tccccgtcgt 3480
gtagataact acgatacggg agggcttacc atctggcccc agtgctgcaa tgataccgcg 3540
agaccacgc tcaccggctc cagatttatc agcaataaac cagccagccg gaagggccga 3600
gcgcagaagt ggtctgcaa ctttatccgc ctccatccag tctattaatt gttgccggga 3660
agctagagta agtagttcgc cagttaatag tttgcgcaac gttgttgcca ttgctacagg 3720
catcgtgggtg tcacgctcgt cgtttggtat ggcttcattc agctccggtt cccaacgate 3780
aaggcgagtt acatgatccc ccatgttgtg caaaaaagcg gttagctcct tcggtcctcc 3840
gatcgttgtc agaagtaagt tggccgcagt gttatcactc atggttatgg cagcactgca 3900
taattctctt actgtcatgc catccgtaag atgcttttct gtgactgggt agtactcaac 3960
caagtcattc tgagaatagt gtatcgggcg accgagttgc tcttgcccgg cgtcaatacg 4020
ggataatacc gcgccacata gcagaacttt aaaagtgtct atcattggaa aacgttcttc 4080
ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt aaccactcgt 4140
tgcacccaac tgatcttcag catcttttac tttaccagc gtttctgggt gagcaaaaac 4200
aggaaggcaa aatgccgcaa aaaagggaat aaggcgacac cggaaatgtt gaatactcat 4260
actcttcctt tttcaatatt attgaagcat ttatcagggg tattgtctca tgagcggata 4320
catatttgaa tgtatttaga aaaataaaca aataggggtt ccgcgcacat ttccccgaaa 4380
agtgccac

```

<210> 4  
 <211> 2299  
 <212> DNA

<213> Artificial Sequence

<220>

<223> expression construct

<221> misc\_feature

<222> 495

<223> n = A,T,C or G

<400> 4

```

ttaaacagat ctggcctccg cgcggggttt tggcgccctcc cgcggggcgcc cccctcctca 60
cggcgagcgc tgcacgctca gacgaagggc gcagcgagcg tcctgacctt tccgcccgga 120
cgctcaggac agcggcccg cgtcataag actcggcctt agaaccacag tatcagcaga 180
aggacatttt aggacgggac ttgggtgact ctagggcact ggttttcttt ccagagagcg 240
gaacaggcga ggaaaagtag tcccttctcg gcgattctgc ggagggatct ccgtggggcg 300
gtgaacgcgc atgattatat aaggacgcgc cgggtgtggc acagctagtt ccgtcgcagc 360
cgggatttgg gtcgcggttc ttgtttgtgg atcgtctgta tcgtcacttg gtgagtagcg 420
ggctgctggg ctggccgggg ctttcgtggc cgcggggcgc ctcggtggga ccgaagcggtg 480
tggagagacc gccangggct gtagtctggg tcccgcgagc aaggttgccc tgaactgagg 540
ggttgggggg gagcgagca aaatggcggc tgttcccgag tctgaatgga agacgcctgt 600
gaggcgggct gtgaggtcgt tgaacaagg tggggggcat ggtgggcggc aagaacccaa 660
ggtcttgagg ccttcgctaa tgcgggaaag ctcttattcg ggtgagatgg gctggggcac 720
catctgggga cctgacgtg aagtttgtca ctgactggag aactcggttt gtcgtctgtt 780
gcggggggcg cagttatggc ggtgccgttg ggagtgac ccgtaccttt gggagcgcgc 840
gccctcgtcg tgtcgtgacg tcaccggttc tgttggtacc gaattcaggg tggggccacc 900
tgccggtagg tgtgcggtag gcttttctcc gtgcgaggac gcagggttcg ggctagggtt 960
aggtctcctt gaatcgacag gcgcgggacc tctgggtgagg ggagggataa gtgaggcgct 1020
agtttctttg gtcggtttta tgtacctatc ttcttagtag ctgaagctcc ggttttgaac 1080
tatgcgctcg gggttggcga gtgtgttttg tgaagttttt taggcacctt ttgaaatgta 1140
atcatttggg tcaatatgta attttcagtg ttagactagt aaattgtccg ctaaattctg 1200
gccgtttttg gcttttttgt tagacgaagc ttgatatacat ctgcaggcgg ccgcagaaca 1260
aaaactcctc tcagaagagg atctggtgca gccggtcgcc accatggtga gcaagggcga 1320
ggagctgttc accgggggtg tgcccatcct ggtcgagctg gacggcgacg taaacggcca 1380
caagttcagc gtgtccggcg agggcgaggg cgatgccacc tacggcaagc tgacctgaa 1440
gttcattctg accaccggca agctgccctg gccctggccc accctcgtga ccacctgac 1500
ctacggcggt cagtgcttca gccgtaccc cgaccacatg aagcagcacg acttcttcaa 1560
gtccgccatg cccgaaggct acgtccagga gcgcaccatc ttcttcaagg acgacggcaa 1620
ctacaagacc cgcgcgaggg tgaagttcga gggcgacacc ctggtgaacc gcatcgagct 1680
gaagggcatc gacttcaagg aggacggcaa catcctgggg cacaagctgg agtacaacta 1740
caacagccac aacgtctata tcatggccga caagcagaag aacggcatca aggtgaactt 1800
caagatccgc cacaacatcg aggacggcag cgtgcagctc gccgaccact accagcagaa 1860
caccctcatc ggcgacggcc ccgtgctgct gcccgacaac cactacctga gcacctgac 1920
cgccctgagc aaagacccca acgagaagcg cgatcacatg gtccgtgctg agttcgtgac 1980
cgccgcgggg atcactctcg gcatggacga gctgtacaag taaagcggcc gcgactctag 2040
atcataatca gccataccac atttgtagag gttttacttg ctttaaaaaa cctcccacac 2100
ctccccctga acctgaaaca taaaatgaat gcaattgttg ttgttaactt gtttattgca 2160
gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatttttt 2220
tactgcatc ctagttgtgg tttgtccaaa ctcatcaatg tatcttaaga ccggttagca 2280
ggcatgctgg ggatgcggt
2299

```

<210> 5

<211> 2301

<212> DNA

<213> Artificial Sequence

<220>

<223> expression construct

<221> misc\_feature

<222> 532

<223> n = A,T,C or G

&lt;400&gt; 5

```

ttaaacagat ctggcctccg cgccgggttt tggcgccctcc cgcggggcgcc cccctcctca 60
cggcgagcgc tgccacgtca gacgaagggc gcagcgagcg tccctgaccc tccgcccgga 120
cgctcaggac agcggcccg cgtcctaaag actcggcctt agaaccaccag tatcagcaga 180
aggacatttt aggacgggac ttgggtgact ctaggggcact ggttttcttt ccagagagcg 240
gaacaggcga ggaaaagtag tcccttctcg gcgattctgc ggagggatct ccgtggggcg 300
gtgaacgcgc atgattatat aaggacgctc gatccctatc agtgatagag atccctatca 360
gtgatagaga ctagcgcaca gctagtcccg tcgcagcccg gatttggttc gccgttctttg 420
tttgtggatc gctgtgatcg tcacttggtg agtagcgggc tgctgggctg gccggggcctt 480
tcgtggccgc cgggcccgtc ggtgggaccg aagcgtgtgg agagaccgcc angggctgta 540
gtctgggtcc cgcgagcaag gttgccctga actgaggggt tgggggggag cgcagcaaaa 600
tggcggctgt tcccagatct gaatggaaga cgcctgtgag cggggctgtg aggtcgttga 660
aacaagggtg ggggcatggt gggcggcaag aaccaagggt cttgaggcct tcgctaattg 720
gggaaagctc ttattcgggt gagatgggct ggggcacccat ctggggaccg tgacgtgaag 780
tttgtcactg actggagaac tcggtttgtc gtctgttgctg ggggcggcag ttatggcggt 840
gccgttggtg agtgacccg tacctttggg agcgcgcgcc ctgcgtcgtg cgtgacgtca 900
ccggttctgt tggtaaccga ttccagggtg ggcacacctg cggtaggtgt gcggtaggct 960
tttctccgtc gcaggacgca ggttcggggc ctagggtagg ctctcctgaa tcgacaggcg 1020
ccggacctct ggtgagggga gggataagtg aggcgtcagt ttctttggtc ggttttatgt 1080
acctatcttc tttagtagct gaagctccgg ttttgaacta tgcgctcggg gttggcgagt 1140
gtgttttgtg aagtttttta ggcacctttt gaaatgtaat catttggtgc aatatgtaat 1200
tttcagtgtt agactagtaa attgtccgct aaattctggc cgtttttggc ttttttgtta 1260
gacgaagctt gatcatctc gcaggcgccc gcagaacaaa aactcatctc agaagaggat 1320
ctggtgcagc cggtcgccac catggtgagc aaggcgagag agctgttcac cggggtggtg 1380
cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt gtccggcgag 1440
ggcgagggcg atgccaccta cggcaagctg accctgaagt tcactctgac caccggcaag 1500
ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcgtgca gtgcttcagc 1560
cgctaccccg accacatgaa gcagcacgac ttcttcaagt ccgccatgcc cgaaggctac 1620
gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagaccgc cgccgaggtg 1680
aagttcgagg gcgacacct ggtgaaccgc atcgagctga agggcatcga cttcaaggag 1740
gacggcaaca tcctggggca caagctggag tacaactaca acagccacaa cgtctatata 1800
atggccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca caacatcgag 1860
gacggcagcg tgcagctcgc cgaccactac cagcagaaca ccccatcgg cgacggcccc 1920
gtgctgctgc ccgacaacca ctacctgagc acccagtcgg ccctgagcaa agaccccaac 1980
gagaagcgcg atcacatggt cctgctggag ttctgtgacc cgcgggggat cactctcggc 2040
atggacgagc tgtacaagta aagcggccgc gactctagat cataatcagc cataccacat 2100
ttgtagaggt tttacttgct ttaaaaaacc tcccacacct cccctgaac ctgaaacata 2160
aaatgaatgc aattgttgtt gttaacttgt ttattgcagc ttataatggt taaaaataaa 2220
gcaatagcat cacaattttc acaataaaag catttttttc actgcattct agttgtggtt 2280
tgtccaaact catcaatgta t 2301

```

&lt;210&gt; 6

&lt;211&gt; 2300

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; expression construct

&lt;221&gt; misc\_feature

&lt;222&gt; 531

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 6

```

ttaaacagat ctggcctccg cgccgggttt tggcgccctcc cgcggggcgcc cccctcctca 60
cggcgagcgc tgccacgtca gacgaagggc gcagcgagcg tccctgaccc tccgcccgga 120
cgctcaggac agcggcccg cgtcctaaag actcggcctt agaaccaccag tatcagcaga 180
aggacatttt aggacgggac ttgggtgact ctaggggcact ggttttcttt ccagagagcg 240
gaacaggcga ggaaaagtag tcccttctcg gcgattctgc ggagggatct ccgtggggcg 300
gtgaacgcgc atgattatat aaggacgcg cgggtgtggc acagctagtt ccgtcgcagc 360

```

```

cgggatttgg gtctcgatcc ctatcagtga tagagatccc tatcagtgat agagactagc 420
ttgtggatcg ctgtgatcgt cacttgggtga gtacgaggct gctgggctgg ccggggcttt 480
cgtggccgcc ggcccgctcg gtgggaccga agcgtgtgga gagaccgcca ngggctgtag 540
tctgggtccc gcgagcaagg ttgccctgaa ctgaggggtt gggggggagc gcagcaaaat 600
ggcggctgtt cccgagtctg aatggaagac gcctgtgagg cgggctgtga ggtcgttgaa 660
acaagggtggg gggcatggtg ggcgcaaga acccaaggct ttgaggcctt cgctaatacg 720
ggaaagctct tattcgggtg agatgggctg gggcaccatc tggggaccct gacgtgaagt 780
ttgtcactga ctggagaact cggtttgtcg tctgttgccg gggcggcagt tatggcgggtg 840
ccgttggggc gtgcaccctg acctttggga gcgcgcgcc tcgtcgtgtc gtgacgtcac 900
ccgttctggt ggtaccgaat tcagggtggg gccacctgcc ggtaggtgtg cgttaggctt 960
ttctcgtcg caggacgcag ggttcgggcc tagggtaggc tctcctgaat cgacaggcgc 1020
cggacctctg gtgaggggag ggataagtga ggcgtcagtt tctttggtcg gttttatgta 1080
cctatcttct ttagtagctg aagctccggt tttgaactat gcgctcgggg ttggcgagt 1140
tgttttgtga agtttttttag gcaccttttg aaatgtaatc atttgggtca atatgtaatt 1200
ttcagtgtta gactagtaaa ttgtccgcta aattctggcc gtttttggct tttttgttag 1260
acgaagcttg atatcatctg caggcggccg cagaacaaaa actcatctca gaagaggatc 1320
tggtgcagcg gtcgccacc atggtgagca agggcgagga gctgttcacc ggggtgggtgc 1380
ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg 1440
gcgagggcga tggcacctac ggcaagctga ccctgaagtt catctgcacc accggcaagc 1500
tgcccggtgc ctggccacc ctctgaccca ccctgacctc cggcgtgcag tgcttcagcc 1560
gtaccccgca ccacatgaag cagcacgact tcttcaagtc cgccatgcc gaaggtacg 1620
tccaggagcg caccatcttc ttcaaggacg acggcaacta caagaccgc gccgaggtga 1680
agttcgagg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg 1740
acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac gtctatatca 1800
tggccgacaa gcagaagaac ggcatcaagg tgaacttcaa gatccgccac aacatcgagg 1860
acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcggc gacggccccg 1920
tgctgctgcc cgacaaccac tacctgagca cccagtccgc cctgagcaaa gaccccaacg 1980
agaagcgcgga tcacatggtc ctgctggagt tcgtgaccgc cgccgggagc actctcggca 2040
tggacgagct gtacaagtaa agcggcccg gtactatgatc ataatacagc ataccacatt 2100
ttagaggtt ttaactgtct taacaaacct cccacacctc cccctgaacc tgaaacataa 2160
aatgaatgca attgttgggt ttaacttgggt tattgcagct tataatgggt acaataaag 2220
caatagcatc acaaatttca caaataaagc atttttttca ctgcattcta gttgtgggtt 2280
gtccaaactc atcaatgtat                                     2300

```

&lt;210&gt; 7

&lt;211&gt; 3850

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; expression construct

&lt;221&gt; misc\_feature

&lt;222&gt; 531

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 7

```

ttaaacagat ctggcctccg cgccgggttt tggcgccctc cgcgggcgcc cccctcctca 60
cggcgagcgc tgccacgtca gacgaaggcg gcagcgagcg tcctgatcct tccgcccgga 120
cgctcaggac agcggccgcg tgctcataag actcggcctt agaaccocag tatcagcaga 180
aggacatttt aggacgggac ttgggtgact ctagggcact ggttttcttt ccagagagcg 240
gaacaggcga ggaaaagtag tcccttctcg gcgattctgc ggagggatct ccgtggggcg 300
gtgaacgcgg atgattatat aaggacgcgc cgggtgtggc acagctagtt ccgtcgcagc 360
cgggatttgg gtctcgatcc ctatcagtga tagagatccc tatcagtgat agagactagc 420
ttgtggatcg ctgtgatcgt cacttgggtga gtacgaggct gctgggctgg ccggggcttt 480
cgtggccgcc gggccgctcg gtgggaccga agcgtgtgga gagaccgcca ngggctgtag 540
tctgggtccc gcgagcaagg ttgccctgaa ctgaggggtt gggggggagc gcagcaaaat 600
ggcggctgtt cccgagtctg aatggaagac gcctgtgagg cgggctgtga ggtcgttgaa 660
acaagggtggg gggcatggtg ggcgcaaga acccaaggct ttgaggcctt cgctaatacg 720
ggaaagctct tattcgggtg agatgggctg gggcaccatc tggggaccct gacgtgaagt 780
ttgtcactga ctggagaact cggtttgtcg tctgttgccg gggcggcagt tatggcgggtg 840

```



```

ccgttgggca gtgcacccgt acctttggga gcgcgcgccc tcgtcgtgtc gtgacgtcac 900
ccgttctgtt ggtacctgct gttgacagt agcgaccaag ggagattcgt tgcaactcag 960
tgaagccaca gatgtgagtt gtaacatctc ccttggctgc ctactgcctc ggacttcaag 1020
ggaattcagg gtggggccac ctgccggtag gtgtgcggtg ggcttttctc cgtcgcagga 1080
cgcagggttc gggcctaggg taggctctcc tgaatcgaca ggcgccggac ctctggtgag 1140
gggaggggata agtgaggcgt cagtttcttt ggtcggtttt atgtacctat cttctttagt 1200
agctgaagct ccggttttga actatgcgct cgggggttggc gagtgtgttt tgtgaagttt 1260
tttaggcacc ttttgaaatg taatcatttg ggtcaatatg taattttcag tgttagacta 1320
gtaaattgtc cgctaaattc tggccggttt tggctttttt gttagacgaa gcttgatata 1380
accatgtcca gattagataa aagtaaagtg attaacagcg cattagagct gcttaatgag 1440
gtcggaaatc aaggtttaac aacccgtaaa ctgcgccaga agctagggtg agagcagcct 1500
acattgtatt ggcacgtgcg caacaagcag actcttatga acatgctttc agaggcaata 1560
ctggcgaagc atcacacccg ttcagcaccg ttaccgactg agagtgggca gcagtttctc 1620
caggaaaatg ctctgagttt ccgtaaagca ttactggtcc atcgtgatgg agcccgattg 1680
catataggga cctctcctac gcccccccag tttgaacaag cagaggcgca actacgctgt 1740
ctatgcgatg cagggttttc ggtcggaggag gctcttttca ttctgcaatc tatcagccat 1800
tttacgttgg gtgcagtatt agaggagcaa gcaacaaacc agatagaaaa taatcatgtg 1860
atagacgctg caccaccatt attacaagag gcatttaata ttcaggcgag aacctctgct 1920
gaaatggcct tccatttcg gctgaaatca ttaattttg gatttttctg acagtttagca 1980
ttaatatatt gattttctgc acagtttagat gaaaaaaagc atacacccat tgaggatggt 2040
aataaaccaa aaaagaagag aaagctggca gtgtcagtga catttgaaga tgtggctgtg 2100
ctctttactc gggacgagtg gaagaagctg gatctgtctc agagaagcct gtaccgtgag 2160
gtgatgctgg agaattacag caacctggcc tccatggcag gattcctgtt taccaaacca 2220
aagggtgatc ccctgttgca gcaaggagag gatccctggt aagcggcctc gagctcaagc 2280
ttcgaattct gcagtcgacg gtaccgcggg cccgggatcc gcccctctcc ctcccccccc 2340
cctaacgtta ctggccgaag ccgcttgaa taaggccggt gtgcgtttgt ctatatgtta 2400
ttttccacca tattgccgtc ttttggcaat gtgaggggcc ggaaacctgg cctgtcttc 2460
ttgacgagca ttcttagggg tctttccctc ctgcgcaaag gaatgcaagg tctgttgaat 2520
gtcgtgaagg aagcagttcc tctggaagct tcttgaagac aaacaacgtc tgtagcgacc 2580
ctttgcaggc agcggaaacc cccacctggc gacaggtgcc tctgcggcca aaagccacgt 2640
gtataagata cacctgcaaa ggccgcacaa cccagtgcc acgttgtgag ttggatagtt 2700
gtggaagag tcaaatggct ctctcaagc gtattcaaca aggggctgaa ggatgccag 2760
aaggtagccc attgtatgg atctgatctg gggcctcggg gcacatgctt tacatgtgtt 2820
tagtcgaggt taaaaaacg tctaggcccc ccgaaccacg gggacgtggt tttcctttga 2880
aaaacacgat gataatatg ccacaacat ggtgagcaag ggcgaggagc tgttcaccgg 2940
gggtggtccc atcctggtcg agctggacgg cgacgtaaac ggccacaagt tcagcgtgtc 3000
cggcgagggc gagggcgatg ccacctacgg caagctgacc ctgaagtcca tctgcaccac 3060
cggcaagctg ccctgcccct ggcccaccct cgtgaccacc ctgacctacg gcgtgcagtg 3120
cttcagccgc taccgacc acatgaagca gcacgacttc ttcaagtccg ccctgcccga 3180
aggctacgtc caggagcgca ccatcttctt caaggacgac ggcaactaca agaccgcgc 3240
cgaggtgaag ttcgagggcg acacctggt gaaccgcac gagctgaagg gcatcgactt 3300
gccacaacgt ctatatcatg gccgacaagc agaagaacgg catcaagggt aacttcaaga 3360
tccgccacaa catcgaggac ggcagcgtgc agctcgccga ccactaccag cagaacccc 3420
ccatcgcgga cggccccgtg ctgctgccc acaaccacta cctgagcacc cagtcgcgcc 3480
tgagcaaaga ccccaacgag aagcgcgatc acatggctct gctggagttc gtgaccgccg 3540
ccgggatcac ctccggcatg gacgagctgt acaagtaaag cggccgcgac tctagatcat 3600
aatcagccat accacatttg tagaggtttt acttgcttta aaaaacctcc cacacctccc 3660
cctgaacctg aaacataaaa tgaatgcaat tgttgttgtt aacttgttta ttgcagctta 3720
taatggttac aaataaagca atagcatcac aaatttcaca aataaagcat ttttttact 3780
gcattctagt tgtggtttgt ccaaactcat caatgtatct taagaccggt tagcaggcat 3840
gctggggatg 3850

```

&lt;210&gt; 8

&lt;211&gt; 4300

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; expression construct

&lt;221&gt; misc\_feature

&lt;222&gt; 536, 2369

&lt;223&gt; n = A, T, C or G

&lt;400&gt; 8

```

ttaaacagat ctggcctccg cgcggggttt tggcgccctcc cgcggggcgcc cccctcctca 60
cggcgagcgc tgccacgtca gacgaagggc gcagcgagcg tcctgaccc tccgcccga 120
cgctcaggac agcggcccgc tgctcataag actcggcctt agaaccacag tatcagcaga 180
aggacathtt aggacgggac ttgggtgact ctaggggact ggttttcttt ccagagagcg 240
gaacaggcga ggaagtagt tccgttctcg gcgattctgc ggagggatct ccgtggggcg 300
gtgaacgccg atgattatat aaggacgcgc cgggtgtggc acagctagtt ccgtcgcagc 360
cgggatttgg gtctcgaaat aacttcgtat agcatacatt atacgaagtt atactcgagg 420
ctagcttggt gatcgctgtg atcgtcactt ggtgagtagc gggctgctgg gctggccggg 480
gctttcgtgg ccgcccggcc gctcgggtgg accgaagcgt gtggagagac cgccangggc 540
tgtagtctgg gtcccgcgag caaggttgcc ctgaactgag gggttggggg ggagcgcagc 600
aaaatggcgg ctgttcccga gtctgaatgg aagacgcctg tgaggcgggc tgtgaggtcg 660
ttgaacaag gtggggggca tgggtggcgcg caagaacca aggtcttgag gccttcgcta 720
atcggggaaa gctcttattc gggtgagatg ggctggggca ccactctggg accctgacgt 780
gaagtttgtc actgactgga gaactcgtt tgcgtctgt tgccggggcg gcagttatgg 840
cgggtgccgtt gggcagtgca cccgtacett tgggagcgcg cgccctcgtc gtgtcgtgac 900
gtcaccgcgt ctgttggtac cgaattcagg gtggggccac ctgccggtag gtgtgcgcta 960
ggcttttctc cgtcgcagga cgcagggttc gggcctaggg taggctctcc tgaatcgaca 1020
ggcgccggac ctctggtgag gggagggata agtgaggcgt cagtttcttt ggtcggtttt 1080
atgtacctat tctctttagt agctgaagct ccggttttga actatgcgct cggggttggc 1140
gagtgtgttt tgtgaagttt tttaggcacc ttttgaatg taatcatttg ggtcaatatg 1200
taattttcag tgttagacta gtaaattgtc cgctaaattc tggccgtttt tggctttttt 1260
gttagacgaa gcttgatacc ggtcgccacc atggcctcct ccgagaacgt catcaccgag 1320
ttcatgcgct tcaaggtgag catggagggc accgtgaacg gccacgagtt cgagatcgag 1380
ggcgaggggc agggccgccc ctacgagggc cacaacaccg tgaagctgaa ggtgaccaag 1440
ggcgccccc tgcccttcgc ctgggacatc ctgtccccc agttccagta cggctccaag 1500
gtgtacgtga agcaccgcgc cgacatcccc gactacaaga agctgtcctt ccccgagggc 1560
ttcaagtggg agcgcgtgat gaacttcgag gacggcgggc tggcgaccgt gaccaggac 1620
tctccctgc aggacggctg cttcatctac aagtggaagt tcatcggcgt gaacttccc 1680
tccgacggcc cgtgatgca gaagaagacc atgggctggg aggcctccac cgagcgcctg 1740
taccgccgag acggcggtgt gaaggcgag acccacaagg cctgaagct gaaggacggc 1800
ggccactacc tgggtggagt caagtccatc tacatggcca agaagccgt gcagctgccc 1860
ggctactact acgtggacgc caagctggac atcacctccc acaacgagga ctacaccatc 1920
gtggagcagt acgagcgcac cgagggccgc caccacctgt tctgttagcg gcccgactc 1980
tagatcataa tcagccatac cacatttgta gaggttttac ttgctttaa aaacctccca 2040
cacctcccc tgaacctgaa acataaaatg aatgcaattg ttgttgtaa cttgtttatt 2100
gcagcttata atggttataa ataaagcaat agcatcacia atttcacaaa taaagcattt 2160
ttttcactgc attctagttg tggtttgtcc aaactcatca atgtatctta agaccgaaa 2220
taacttcgta tagcatacat tatacgaagt tatctagett gtggatcgct gtgatcgta 2280
cttgggtgagt agcgggctgc tgggctggcc ggggctttcg tggccgccc ggcgctcgg 2340
gggaccgaag cgtgtggaga gaccgccang ggctgtagtc tgggtcccgc gagcaagggt 2400
gccctgaact gaggggttgg gggggagcgc agcaaaatgg cggctgttcc cgagtctgaa 2460
tggaagacgc ctgtgaggcg ggctgtgagg tcggtgaaac aagggtgggg gcattgggtg 2520
cggcaagaac ccaaggtctt gaggccttcg ctaatgcggg aaagctctta ttcgggtgag 2580
atgggctggg gcaccatctg gggaccctga cgtgaagttt gtcaactgact ggagaactcg 2640
gtttgtcgtc tgttgccggg gcggcagtta tggcggtgcc gttgggcagt gcaccctgac 2700
ctttgggagc gcgcgccctc gtcgtgtcgt gacgtcacc gttctgttgg tacctgctgt 2760
tgacagttag cgaccaagg agattcgttg caactcagtg aagccacaga tgtgagttgt 2820
aacatctccc ttggtgcct actgcctcgg acttcaagg aattcagggt ggggccacct 2880
gccggtaggt gtgcggttag cttttctccg tcgcaggacg cagggttcgg gctagggtta 2940
ggctctcctg aatcgacagg cgcggacct ctggtgagg gagggataag tgaggcgtca 3000
gtttcttttg tcggttttat gtacctatct tcttttagtag ctgaagctcc ggttttgaac 3060
tatgcgctcg gggttggcga gtgtgttttg tgaagtttt taggcacct ttgaaatgta 3120
atcatttggg tcaatatgta attttcagt ttagactagt aaattgtccg ctaaatctcg 3180
gccgtttttg gcttttttgg tagacgaagc ttgatatcat ctgcaggcgg ccgcagaaca 3240
aaaactcatc tcagaagagg atctgggtgca gccggtcgcc accatgggtg gcaaggcgca 3300
ggagctgttc accggggtgg tgccatcctt ggtcgagctg gacggcgacg tacggcaagc tgaccctgaa 3420
caagttcagc gtgtccggcg agggcgaggc cgatgccacc

```

```

gttcattctgc accacccggca agctgcccgt gccctggccc accctcgtga ccaccctgac 3480
ctacggcgctg cagtgtctca gccgtacccc cgaccacatg aagcagcacg acttcttcaa 3540
gtccgcctatg cccgaaggct acgtccagga gccaccatc ttcttcaagg acgacggcaa 3600
ctacaagacc cgcgcggagg tgaagtctga gggcgacacc ctggtgaacc gcacgcagct 3660
gaagggcatc gacttcaagg aggacggcaa catcctgggg cacaagctgg agtacaacta 3720
caacagccac aacgtctata tcatggccga caagcagaag aacggcatca aggtgaactt 3780
caagatccgc cacaacatcg aggacggcag cgtgcagctc gccgaccact accagcagaa 3840
caccctcatc ggcgacggcc ccgtgctgct gcccgacaac cactacctga gcaccagtc 3900
cgccctgagc aaagacccca acgagaagcg cgatcacatg gtccctgctgg agttcgtgac 3960
cgccgcggg atcactctcg gcatggacga gctgtacaag taaagcggcc gcgactctag 4020
atcataatca gccataccac atttgtagag gttttacttg ctttaaaaaa cctcccacac 4080
ctccccctga acctgaaaca taaaatgaat gcaattgttg ttgttaactt gttttattgca 4140
gcttataatg gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatttttt 4200
tactgcatc ctagtgtggt tttgtccaaa ctcatcaatg tatcttaaga ccggttagca 4260
ggcatgctgg ggatgcggtg ggctctatgg cttctgaggg 4300

```

&lt;210&gt; 9

&lt;211&gt; 4200

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; expression construct

&lt;221&gt; misc\_feature

&lt;222&gt; 528, 2516

&lt;223&gt; n = A,T,C or G

&lt;400&gt; 9

```

ttaaaccagat ctggcctccg cgcggggttt tggcgccctcc cgcggggcgcc cccctectca 60
cggcgagcgc tgccacgtca gacgaaggcg gcagcgagcg tccctgatcct tccgcccgga 120
cgctcaggac agcggcccgc tgctcataag actcggcctt agaaccaccag tatcagcaga 180
aggacatttt aggacgggac ttgggtgact ctaggggcact ggttttcttt ccagagagcg 240
gaacaggcga ggaaaagtag tcccttctcg gcgattctgc ggagggatct ccgtggggcg 300
gtgaacgccg atgattatat aaggacgcgc cgggtgtggc acagctagt tccgtcgcagc 360
cgggatttgg gtctcgaaat aacttcgtat agcatacatt atacgaagt atctagcttg 420
tggatccgtg tgatcgtcac ttggtgagta gcggtgctgt gggctggccg gggcttctct 480
ggcgccggg ccgctcggtg ggaccgaagc gtgtggagag accgccangg gctgtagtct 540
gggtcccgcg agcaagggtg ccctgaactg aggggttggg ggggagcgca gcaaaatggc 600
ggctgttccc gagtctgaat ggaagacgcc tgtgaggcgg gctgtgaggt cgttgaaaca 660
agggtggggg catggtgggc ggcaagaacc caaggtcttg aggccttcgc taatgcggga 720
aagctcttat tgggtgaga tgggtcgggg caccatctgg ggaccctgac gtgaagtgtg 780
tactgactg gagaactcgg tttgtcgtct gttgcggggg cggcagttat ggcggtgccc 840
ttgggcagtg caccgtacc tttgggagcg cgcgccctcg tctgtcgtg acgtcaccgc 900
ttctgttggg acctgctgtt gacagtgagc gaccaaggga gattcgttg aactcagtga 960
agccacagat gtgagttgta acatctccct tggctgccta ctgcctcgga cttcaaggga 1020
attcagggtg gggccacctg ccggtaggtg tgcggtaggg ttttctccgt cgcaggacgc 1080
agggttcggg cctagggtag gctctcctga atcgacagg gccggacctc tgggtagggg 1140
agggataagt gaggcgtcag tttctttggg cggttttatg tacctatctt ctttagtagc 1200
tgaagctccg gttttgaact atgcgtcgg ggttggcgag tgtgttttgt gaagtttttt 1260
aggcaccttt tgaatgtaa tcatttgggt caatatgtaa ttttcagtgt tagactagta 1320
aattgtccgc taaattctgg ccgtttttgg atttttgggt agacgaagct tgatatcatc 1380
tgcaggcggc cgcagaacaa aaactcatct cagaagagga tctggtgcag ccggtcgcca 1440
ccatggtgag caagggcgag gagctgttca cgggggtggg gcccatcctg gtcgagctgg 1500
acggcgacgt aaacggccac aagttcagcg tgtccggcga gggcgagggc gatgccacct 1560
acggcaagct gaccctgaag ttcactctga ccaccggcaa gctgcccgtg ccctggccca 1620
ccctcgtgac caccctgacc tacggcgtgc agtgcttcag ccgctacccc gaccacatga 1680
agcagcacga cttcttcaag tccgcatgc ccgaaggcta cgtccaggag cgcaccatct 1740
tcttcaagga cgacggcaac tacaagaccc gcgccagggt gaagtctcag ggcgacaccc 1800
tggtgaaccg catcgagctg aagggcacgc acttcaagga ggacggcaac atcctggggc 1860
acaagctgga gtacaactac aacagccaca acgtctatat catggccgac aagcagaaga 1920

```

acggcatcaa ggtgaacttc aagatccgcc acaacatcga ggacggcagc gtgcagctcg 1980  
 ccgaccacta ccagcagaac caccagtcgc gccctgagca aagaccccaa cgagaagcgc 2040  
 gatcacatgg tcctgctgga gtctgtgacc gccgcggga tctctctcgg catggacgag 2100  
 ctgtacaagt aaagcgcccg cgactctaga tcataatcag ccataccaca tttgtagagg 2160  
 ttttacttgc tttaaaaaac ctcccacacc tccccctgaa cctgaaacat aaaatgaatg 2220  
 caattgttgt tgttaacttg tttattgcag cttataatgg ttacaaataa agcaatagca 2280  
 tcacaaattt cacaaataaa gcattttttt cactgcattc tagttgtggt ttgtccaaac 2340  
 tcatcaatgt atcttaagac cggtataaac ttcgtatagc atacattata cgaagtatatg 2400  
 ctagcttggt gatcgctgtg atcgtcactt ggtgagtagc gggctgctgg gctggccggg 2460  
 gctttcgtgg ccgcggggcc gctcgggtgg accgaagcgt gtggagagac cgccangggc 2520  
 tgtagtctgg gtcccgcgag caaggttgcc ctgaactgag gggttggggg ggagcgagc 2580  
 aaaatggcgg ctgttcccga gtctgaatgg aagacgcctg tgaggcgggc tgtgaggtcg 2640

ttgaaacaag gtggggggca tgggtggcgg caagaaccca aggtcttgag gccttcgcta 2700  
 atgcgggaaa gctcttattc gggtagatg ggctggggca ccactgaggg accctgacgt 2760  
 gaagtttgtc actgactgga gaactcgggt tgcgtctgt tgcgggggcg gcagttatgg 2820  
 cgggtgcggt gggcagtgca ccgcgtacct tgggagcgcg cgccctcgtc gtgtcgtgac 2880  
 gtcacccggt ctgttggtac cgaattcagg gtggggccac ctgcccgtag gtgtgcgta 2940  
 ggctttttct cgtcgagga cgcagggttc gggcctaggg taggctctcc tgaatcgaca 3000  
 ggcgcgggac ctctggtgag gggagggata agtgaggcgt cagtttcttt ggtcggtttt 3060  
 atgtacctat cttctttagt agctgaagct ccggttttga actatgcgct cgggggttggc 3120  
 gagtgtgttt tgtgaagttt tttaggcacc ttttgaaatg taatcatttg ggtcaatatg 3180  
 taattttcag tgttagacta gtaaattgtc cgctaaatc tggccgtttt tggctttttt 3240  
 gttagacgaa gcttgatgtc gccaccatgg cctcctccga gaacgtcatc accgagttca 3300  
 tgcgcttcaa ggtgcgcatg gagggcaccg tgaacggcca cgagttcgag atcgaggcg 3360  
 agggcgaggg ccgcccctac gagggccaca acaccgtgaa gctgaagggt accaaggcg 3420  
 gccccctgcc cttcgctcgg gacatcctgt cccccagtt ccagtacggc tccaagggtg 3480  
 acgtgaagca ccccgccgac atccccgact acaagaagct gtccttcccc gagggcttca 3540  
 agtgggagcg cgtgatgaac ttcgaggacg gcggcggtgg gaccgtgacc caggactcct 3600  
 ccctgcagga cggtgcttc atctacaagg tgaagttcat cggcgtgaac tccccctccg 3660  
 acggccccgt gatgcagaag aagaccatgg gctgggaggg ctcaccgag cgctgtacc 3720  
 cccgcgacgg cgtgctgaag ggcgagacct acaaggccct gaagctgaag gacggcgcc 3780  
 actacctggt ggagttcaag tccatctaca tggccaagaa gcccggtcag ctgccgggt 3840  
 actactacgt ggacgccaag ctggacatca cctcccacaa cgaggactac accatcgtgg 3900  
 agcagtacga gcgcaccgag ggccgccacc acctgttcct gtagcgcccg cgactctaga 3960  
 tcataatcag ccataccaca tttgtagagg ttttacttgc tttaaaaaac ctcccacacc 4020  
 tccccctgaa cctgaaacat aaaatgaatg caattgttgt tgttaacttg tttattgcag 4080  
 cttataatgg ttacaaataa agcaatagca tcacaaattt cacaaataaa gcattttttt 4140  
 cactgcattc tagttgtggt ttgtccaaac tcatcaatgt atcttaagac cggactcgag 4200

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
27 January 2005 (27.01.2005)

PCT

(10) International Publication Number  
**WO 2005/007877 A3**

(51) International Patent Classification<sup>7</sup>: **C12P 19/34**,  
C12N 15/63, 15/11, 15/85, 15/86, 7/00, 15/09, A61K  
48/00, C07H 21/04

(21) International Application Number:  
PCT/US2004/023789

(22) International Filing Date: 19 July 2004 (19.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/488,510 18 July 2003 (18.07.2003) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF MASSACHUSETTS** [US/US]; 365 Plantation Street, Worcester, MA 01605 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **XU, Zuoshang** [US/US]; 11 Ann Drive, North Grafton, MA 01536 (US). **XIA, Xugang** [US/US]; 293 Turnpike Road, Apt. 118, Westborough, MA 01581 (US).

(74) Agents: **MILASINCIC, Debra, J.** et al.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GI, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:  
6 October 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REGULATABLE PROMOTERS FOR SYNTHESIS OF SMALL HAIRPIN RNA

(57) Abstract: The present invention provides compositions for RNA interference and methods of use thereof. The present invention is based on the development of promoters that can be used to regulate shRNA expression spatially (in specific cells) and temporally (at specific times) in cells or transgenic animals that express a recombinase. The compositions and methods of the present invention feature regulatable promoters that allow for inhibition of the expression of target alleles in a spatially and temporally regulatable manner. Thus, the compositions of the present invention are useful for investigating gene functions, both physiologic and pathologic, in specific cell groups and in specific ages, in normal and disease pathways. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.

WO 2005/007877 A3

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/23789

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(7) : C12P 19/34; C12N 15/63, 15/11, 15/85, 15/86, 7/00, 15/09; A61K 48/00; C07H 21/04 US CL : 435/91.4, 325, 235.1, 455; 514/44; 536/23.1, 23.4, 24.1, 24.2, 24.5, 24.31 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/91.4, 325, 235.1, 455; 514/44; 536/23.1, 23.4, 24.1, 24.2, 24.5, 24.31 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, T --- Y	US 2004/0002077 A1 (TAIRA et al.) 1 January 2004 (01.01.2004), pages 1-2, 4-9, Figures, 1-2, 12, 17 and 19-24.	1-23, 72-77 ----- 24-32
X, T  Y	US 2004/0219516 A1 (BENNET et al.) 4 November 2004 (04.11.2004), paragraphs 0051, 0077, 0079, 0164, 0167, 0173, 0219, 0331, 0848. QIN et al. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. PNAS. January 2003, Vol. 100, pages 183-88, especially p. 183, col. 2, last paragraph.	1-32, 72-77  24-32
A	DEVROE et al. Therapeutic potential of retroviral RNAi vectors. Expert. Opin. Biol. Ther. April 2004, Vol. 4, pages 319-327.	
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
- "A" document defining the general state of the art which is not considered to be of particular relevance	- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
- "E" earlier application or patent published on or after the international filing date	- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
- "O" document referring to an oral disclosure, use, exhibition or other means	- "&" document member of the same patent family	
- "P" document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search	Date of mailing of the international search report	
15 May 2005 (15.05.2005)	18 JUL 2005	
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer Ramin (Ray) Akhavan Telephone No. 571-272-0766	

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/23789

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 33-71, 78-80  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Please See Continuation Sheet
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/23789

### Continuation of Box II Reason 2:

Claims 33-71 and 78-80 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because claims are indefinite for the following reason(s): claims 33-71 are multiple dependent claims which are dependent from at least one claim that is itself dependent from multiple claims. For example, claim 33 depends from claim 29 or claim 32, wherein claim 29 depends from either claim 27 or 28 and claim 32 depends from claims 30 or 31. Claims dependent from claim 33 will necessarily suffer from the same vagueness and indefiniteness with respect to defining the claims' metes and bounds. In sum, as written the claims are directed to subject matter, which cannot be defined. In turn, one of skill cannot identify the teachings in the prior art over which the claims may provide an unobvious contribution.

### Continuation of B. FIELDS SEARCHED Item 3:

EPO, USPAT, USPGPUB, JPO, DERWENT, BIOSIS, EMBASE, MEDLINE, GOOGLE: U6 promoter, shRNA, siRNA, RNAi, RNA inhibition, hairpin RNA, loxP, cre recombinase, site specific recombination, TATA box, distal, proximal element, expression inhibition, ds RNA, double stranded RNA, ubiquitin promoter, UBC, tetracycline element, TRE, Tet On, Tet Off, IRES, ribosome entry.